[{"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions. Labor can begin immediately or take a day or two; if it becomes too lengthy, Caesareans are performed.\nDekker said there were flaws in the research showing that women who received elective induction had lower rates of Caesarean delivery. For the women who waited for labor to start on its own, about half ended up being induced for medical complications. \u201cThey still analyzed the data as if the women had spontaneous labor, so it sways the results of the studies,\u201d she said.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story refers to recent studies, but again there are no details provided, so readers are not told what \u201crecent\u201d means. Have the studies been around for years, but just escaped the notice of the featured physicians until they checked the literature in order to prepare for their panel session? Or is there really some important new evidence that wasn\u2019t available when ACOG and other groups issued the latest version of their recommendations about inducing labor? The story doesn\u2019t answer those questions.", "answer": 0}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\nThe researchers behind two studies published Monday demonstrated they had made progress on both fronts, encapsulating the cells in a protective bubble to shield them from the body\u2019s immune response, and creating beta cells from stem cells, which are potentially limitless.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "News stories often don\u2019t address the novelty of a treatment or research finding. But this story actually uses the word \u201cnovel,\u201d which sort of puts a spotlight on the category for us. The story quotes one of the study\u2019s funders calling the protective cell bubbles studied in the research \u201cnovel materials.\u201d We think the story actually does establish their novelty with enough context and caveats.", "answer": 1}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET. For the latest from Sanjay Gupta MD click here.\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\nAgatston thinks the coronary calcium scan should be routinely scheduled at age 50, like a colonoscopy, or earlier for people with family histories of heart disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Coronary calcium scoring has been a hot topic in heart disease prevention for well over a decade. Does it still qualify for the \u201crelatively new\u201d description used in this story? Certainly there is an evolving scientific discussion about which individuals are likely to benefit from these tests, but that sort of nuance is largely missing from this story.", "answer": 0}, {"article": "The FDA recently warned people with peanut allergies to avoid foods containing ground cumin, after traces of peanut powder were found in the ground spice.\nThe patch study's results are promising, although researchers need to continue following the participants for another year, Sampson said. It could be several more years before the patch will be available for consumers.\nIn the skin patch trial, the international team of researchers randomly assigned 221 volunteers, ages 6 to 55, to wear a placebo patch or a patch containing peanut protein at one of three doses: 50 micrograms, 100 micrograms or 250 micrograms.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story alludes to oral immunotherapy \u2014 a similar approach to desensitization that has been more thoroughly tested than the skin patch \u2014 but as noted above, it does not provide any real discussion of how the two compare. Nor does it explain that the patch has already been tested in a pilot study that didn\u2019t find any benefit for the patch over a placebo. What\u2019s different about the current study that led to a higher success rate? A bit more context was needed to satisfy this criterion.", "answer": 0}, {"article": "Elias voted with the majority of an FDA panel that narrowly endorsed the device last year.\nThe company's study was not intended to show that screening with the device saves lives, only that it can help improve a doctor's ability to spot melanoma.\n\"Every day patients come in with 20 moles on their back and the dilemma is, which ones are suspicious and need to be biopsied?\" said Dr. David Pariser, former president of the American Academy of Dermatology. \"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story calls the device a \u201cfirst of its kind,\u201d but it also explains that it is only approved for use in a subset of patients and that much more work needs to be done.", "answer": 1}, {"article": "No serious side effects related to the probiotic were reported, suggesting that such a supplement could be a safe way to treat both stomach- and mood-related symptoms. Studies have looked at various types of probiotics for IBS patients, the authors wrote, and a recent review found that seemed to work better for gastrointestinal symptoms than another common probiotic, .\nFor the new research, scientists from McMaster University in Canada recruited 44 adults with IBS as well as mild to moderate anxiety or depression. They were followed for 10 weeks; half took a daily dose of the probiotic , and half took a placebo. The probiotics were manufactured and provided by Nestle, which also funded the study. (Nestle was not involved in collection, analysis or interpretation of study data.)\n\u201cWe know that one part of the brain, the amygdala, tends to be red hot in people with depression, and it seemed to cool down with this intervention,\u201d says McIntyre, who was not involved in the new research. \u201cIt provides more scientific believability that something in the brain, at a very biological level, seems to be affected by this probiotic.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does a good job of establishing where\u00a0the true novelty of the research lies, which is in the study population used (individuals without IBS and depression or anxiety).", "answer": 1}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids. Exactly how sleep apnea results in bedwetting is not fully understood, but hormonal changes may play a role.\n\"This study really underscores the fact that children who have other issues with sleep should be looked at for bedwetting because anything that depresses sleep at night can lead to bedwetting,\" said AUA spokesman Dr. Anthony Atala, a urologist at Wake Forest University in Winston-Salem, N.C.\n\"If they haven't seen an ear, nose and throat specialist, see one to see if the child who wets the bed has OSA that can be cured by tonsil or adenoid removal,\" said study author Dr. Yegappan Lakshmanan, chief of pediatric urology at Children's Hospital of Michigan, in Detroit.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Treating sleep apnea surgically for bedwetting is not novel, but this story does not make a clear case for novelty or against it.", "answer": 0}, {"article": "And people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n\"The new study is the first to establish a direct relationship between fish consumption, brain structure, and Alzheimer's risk,\" Raji says.\nIn a new study, imaging scans showed that regular fish-eaters were less likely to have brain cells die off in the area of the brain responsible for short-term memory -- recalling a phone number that was just heard, for example.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least stated that \u201cthe new study is the first to establish a direct relationship between fish consumption, brain structure and Alzheimer\u2019s risk\u201d and that \u201cSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer\u2019s disease.\u201d\n ", "answer": 1}, {"article": "Can a cup of blueberries keep the doctor away? Maybe.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines. But, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them. \u201cThere is something very special about the composition of blueberries that is responsible for their effect on blood pressure,\u201d she said. \u201cOther fruits and plant extracts have not produced the same result.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not mention or discuss the novelty of the research or the health claims associated with blueberries. The study upon which the story is based references several prior studies of blueberries, or a plant-rich diet, and hypertension.", "answer": 0}, {"article": "One is that the drug appears to ignore benign forms of amyloid protein while attacking the toxic forms thought to damage brain cells. Another is that aducanumab seems to enhance the ability of existing immune cells in the brain to devour toxins, including amyloid.\n\"If that hint of a clinical benefit is confirmed, it would be a game changer in the fight against Alzheimer's disease,\" says Dr. Eric Reiman, executive director of the Banner Alzheimer's Institute in Phoenix. Reiman wrote a commentary that accompanies the study in Nature.\nOfficials of Biogen, which is developing the drug, were also cautious about interpreting the results of the study, which included 165 patients in the early stages of Alzheimer's disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes what appears to be novel about this drug compared with others that reduce amyloid plaques.\nOne is that the drug appears to ignore benign forms of amyloid protein while attacking the toxic forms thought to damage brain cells. Another is that aducanumab seems to enhance the ability of existing immune cells in the brain to devour toxins, including amyloid.\nBut while the story is clear that the new paper is presenting details of research first reported last year, it doesn\u2019t explain why the results are now \u201cremarkable\u201d whereas last year they were considered \u201cdisappointing,\u201d\u00a0\u201cmixed\u201d\u00a0and a \u201csetback.\u201d\nWe\u2019ll rate this a borderline Satisfactory.", "answer": 1}, {"article": "Some experts contend that allergists resist blood testing in part to protect their revenue. \u201cA barrier to allergy testing in the states has been the economics in our system,\u201d said Dr. Richard G. Roberts, professor of family medicine at the University of Wisconsin School of Medicine and Public Health. If an allergist does an in-office skin-prick test, he gets the fees for those tests. If he requests a blood test, the laboratory gets the fee.\nDr. Roberts says that if primary-care physicians used the blood test, many more patients would be treated appropriately. While most allergy patients are seen by these generalists, he says, many allergies are not adequately diagnosed.\nDr. Hugh Sampson, a food allergy expert at Mount Sinai School of Medicine in New York, is seeking to add a level of precision to diagnosis. He correlates levels of specific IgE with a probability that the person is allergic to a food \u2014 a technique, he says, that reduces the need for food challenge testing by half.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does state that the blood tests were developed in the 1970s but that newer tests have become available more recently.", "answer": 1}, {"article": "Having an optimistic outlook on life may do more than just boost your mood. It may actually help you live longer, according to new research from the Harvard T.H. Chan School of Public Health.\nWhile the study is observational and cannot prove a cause-and-effect relationship between optimism and a longer life, the researchers have some theories for what might be behind the connection.\nFor the study, the researchers analyzed data on from 2004 to 2012 on 70,000 women who participated in the Nurses\u2019 Health Study, a long-running research project tracking women\u2019s health via surveys every two years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story\u00a0explains what\u2019s novel here is how the research looks at all-cause mortality vs specific health behaviors and outcomes. This is established with this statement:\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News. \u201cSo in our study we wanted to expand that and look at all-cause mortality\u00a0and be able to see whether optimism improves other health behaviors that then affects mortality, or whether there\u2019s an independent effect of optimism on mortality.\u201d", "answer": 1}, {"article": "ZURICH (Reuters) - An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.\n\u201cPIK3CA mutations are present in many other tumor types,\u201d Hirawat said. \u201cThere is a larger program we are putting into place.\u201d\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "We learn\u2013via the lead researcher\u2013that this trial provides the \u201cmost encouraging\u201d results to date in a study looking at a PI3K inhibitor in breast cancer. That establishes novelty, but we think the story should have sought independent expert viewpoint to provide context on the limitations of the results, which were based on progression-free survival and not overall survival.\nIt does not include the information that one other PI3K inhibitor is currently on the market and used to treat a type of lymphoma.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes it clear that cupping therapy is not a new approach, as it was \u201cperformed traditionally in China and other countries.\u201d Even the headline reads, \u201cCenturies-Old Art of Cupping May Bring Some Pain Relief.\u201d", "answer": 1}, {"article": "Vivus hopes the FDA will agree that those benefits will outweigh some of the risks, including the concerns about birth defects. The company is submitting new data it says show that the risk is lower than had been feared. Vivus also has a plan to minimize the chances that pregnant women will take it.\n\"There's been a long history with obesity drugs that we've had to take off the market. You recall the fen-phen episode where a significant number of people got heart-valve defects,\" says Janet Woodcock, a top FDA official.\nWoodcock argues that the agency has to be extra-careful with weight-loss drugs, because chances are it won't just be obese people taking them.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As the caption under the story\u2019s photo explains, \u201cThe FDA hasn\u2019t approved a new weight-loss drug since 1999.\u201d\u00a0 But the story didn\u2019t explain, as a Bloomberg story did, that \u201cQnexa is one of three obesity drugs vying to be the first in 13 years on the market.\u201d\u00a0 We think that was an important angle to include.\nIt also could have explained that Qnexa is a combination of two drugs that are well known to cause weight loss (phentermine, the phen in phen-fen and topiramate an antiseizure drug that has weight loss as a side effect).", "answer": 0}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular. Some are combined with defibrillators, which give the heart a major jolt when needed.\nIn the new study, researchers implanted the pacemaker in 32 people for the first time through a puncture in the skin; in 10 patients, they had to reposition it. The researchers reported positive results at up to three months. However, one patient died of a stroke while convalescing after suffering a heart injury during implantation and another had the pacemaker replaced with a defibrillator.\nWhy get a wire-free pacemaker? \"For patients with heart problems, this could potentially mean fewer infections related to leads and less discomfort during the implant procedure,\" Reddy said. And children who get pacemakers wouldn't face chest scarring, he added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Even a quick online search shows that there are other wireless pacing devices in various stages of testing as well, yet the story makes no mention of these.", "answer": 0}, {"article": "\u2022 and a 30 percent lower risk of dying from colon cancer.\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\nFor the study, Potluri and colleagues collected data on nearly 1 million patients listed in a clinical database from January 2000 to March 2013. The database includes information on cancer and other medical conditions, including high cholesterol. Data on deaths was obtained from the U.K. Office for National Statistics.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish the novelty for this particular association of statins with decreased cancer risk. There have been a number of large meta-analyses and retrospective studies about statins and cancer risk reduction (all showing different findings), and this latest result should have been placed in context within the body of research.\nIt is implied (but not stated) that perhaps the use of 1 million patient records is the largest study searching for the correlation \u2013 but the story does not state it.", "answer": 0}, {"article": "Currently, most aspects of cataract surgery, including the initial incision and the breakup and removal of the clouded lens from the lens capsule, are performed manually by the surgeon. An ultrasound instrument with a vibrating needle is used to break up the cataracts, and a vacuum sucks them out.\nThe new studies looked at using the so-called femtosecond laser to deliver near-infrared light to fragment the cataract into tiny segments prior to removal.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not exaggerate the novelty of this procedure, which is just starting to be evaluated clinically.", "answer": 1}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that Erbitux was first used to treat colon cancer, but is now approved to treat head and neck cancer.", "answer": 1}, {"article": "Then the larvae crawl out of the lung through your stomach and into the small intestine \u2014 where they bite onto the intestinal wall and start sucking blood \u2014 a few drops a day.\nThe bottom line: \"The proportion of patients who improved with the worms was no different than the proportion of patients who were improved with placebo,\" says Dr. Stephen Hanauer at Northwestern University Feinberg School of Medicine, who was involved with one trial.\nOther trials with worms haven't gone so well either, says Hanauer. \"The controlled trials, thus far, in a variety of different diseases including childhood allergies and asthma have not been positive.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes novelty by letting us know that studies go back a few years, so it\u2019s not a new concept.", "answer": 1}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of this class of \"self-injectable biologic\" drugs was discussed in the story. ", "answer": 1}, {"article": "Liver cancer is the second-leading primary cause of cancer-related deaths worldwide.\n\"This study represents a breakthrough in the management of hepatocellular carcinoma, since it provides evidence for clinical benefits in an area that was an unmet medical need,\" said Josep M. Llovet, MD, founder and Director of the Liver Cancer Program and Professor of Medicine and Liver Diseases at the Icahn School of Medicine at Mount Sinai. \"Regorafenib has shown it can improve survival in patients with advanced hepatocellular carcinoma progressing on sorafenib. Previously, no treatment was available for these patients.\"\nDr. Llovet was a member of the clinical trial's steering committee, and Charissa Chang, MD, Assistant Professor of Medicine and Liver Diseases at the Icahn School of Medicine, was principal investigator of the Mount Sinai testing site.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release makes clear that this is only the second pharmaceutical treatment for HCC proven to affect patient survival, and outlines what the study findings may mean for future research on how regorafenib may be used in treating earlier stages of HCC.", "answer": 1}, {"article": "The FDA\u2019s approval is limited to treatment of the three types of noninfectious uveitis that pose the greatest threat of vision loss. Glenn Jaffe, M.D., a professor in the Department of Ophthalmology at Duke University School of Medicine, said adalimumab works to treat uveitis by targeting a protein that is thought to promote inflammation. Jaffe led one of two clinical studies that formed the basis of the FDA\u2019s approval and was senior author of the study appearing Sept. 8 in the New England Journal of Medicine (NEJM).\n\u201cUsing these multiple, possible endpoints was something unique to this study,\u201d Jaffe said. \u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\u201cPatients may have many unwanted side effects when taking steroids long-term, as many uveitis patients do,\u201d Jaffe said. \u201cThe goal of these studies was to determine whether there was an alternative that could replace or minimize the use of steroids. The studies also looked at whether an alternative would be better tolerated or more effective, yet still safe.\u201d\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The novelty is somewhat nuanced, but explained well enough: Uveitis is a bag full of symptoms, and the damage involved can span across the entire eye. By measuring how it affected the most frequent symptoms, \u201cthe study\u2019s results broaden the applicability of treatment for patients\u201d and possibly help lead to longer-term solutions for uveitis.", "answer": 1}, {"article": "Public Relations Manager (School of Medicine and Dentistry) \n\"The study needs to be interpreted with caution because it is based on self-reported data, and further studies using objective measures are needed. However, the present results provide sufficient information to suggest that vaping does not increase infection rates and may in fact lead to a decrease in infections.\"\nThe researchers say that it is not surprising that the survey respondents noticed improvements in their respiratory health. This is because smoking increases susceptibility to respiratory infections and stopping smoking can be expected to have a positive effect. In addition to this, vaping may also provide some antimicrobial protection through the e-liquid ingredient propylene glycol, though further evidence is needed to confirm this.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release is not the novelty of e-cigarettes but the novelty of the research. We give it a satisfactory for including this statement which puts the research in context:\n\u201cSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels. Human trials have reported no significant adverse respiratory effects associated with e-cigarette use for up to 1.5 years and a follow-up study of smokers with asthma who switched to vaping found significant improvements.\u201d", "answer": 1}, {"article": "However, experts caution that it is possible to overdo it, and more exercise than two and a half hours a week can actually be unhelpful and even harmful. One study, published in 2014 in the journal Heart, suggests that in people with existing heart disease, the risk for cardiac arrest and stroke was the same for people who exercised more than an hour a day compared with those who didn\u2019t exercise at all. The coronary heart disease patients who stuck with the recommended 150 minutes a week had the lowest risk for heart attack and stroke.\nThis study shows that it doesn\u2019t matter how you decide to split up the recommended weekly amount of exercise. You just need to do it.\n\u201cI think that the weekend warrior physical activity pattern is beneficial because they are actually doing a large proportion of vigorous intensity activity. And vigorous activity makes you fit, and fitness reduces your risk of disease and death,\u201d says Gary O\u2019Donovan, a researcher in physical activity and sedentary behavior at England\u2019s Loughborough University and lead author of the paper.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story did not establish what\u2019s novel, unlike what we saw in our review of The Guardian\u2019s story.", "answer": 0}, {"article": "Overall, there were no programming-related adverse effects, unanticipated adverse device effects, reported neurological deficits or instances of mortality in the study population. Adverse effects such as headache and infection occurred in 11.9% (5 of 42) of the patients in this study, consistent with rates reported in other DBS trials.\n\"The first phase of this study was designed to evaluate the 90-day postoperative safety of this particular surgical method. While the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population. The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\nDr. Ponce adds that the next step is evaluating the efficacy and longer-term safety of the treatment, which will not be known until the last patient completes the two-year evaluation later this year.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release implies novelty by stating that the research \u201chelps pave the way\u201d for a new treatment option. Deep brain stimulation is used for other brain disorders, so it is obviously not a new device or new surgical approach, and the release makes this clear. However, as an approach to treat Alzheimer\u2019s disease it is novel.", "answer": 1}, {"article": "* Average reductions of 0.8 pct seen in levels of A1C\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\nMultiple daily injections remain the most common approach to controlling blood sugar levels. Bergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe novelty of insulin pumps and monitoring sensors was not part of this story.", "answer": 2}, {"article": "In addition, past trials comparing antiseptics before surgery included relatively few participants and often compared a chlorhexidine-alcohol combination with iodine alone. These studies could not determine whether the worse performance of iodine alone was due to the chlorhexidine, the alcohol or the combination.\nA new study from Washington University School of Medicine in St. Louis offers strong guidance on the best way to reduce the infection risk. Rather than prepping patients with iodine-alcohol \u2014 a common antiseptic combination in C-sections \u2014 the research indicates that chlorhexidine-alcohol is significantly more effective. The researchers argue that the evidence is strong enough to change standard skin-prep practices for C-sections.\n\u201cOne of the biggest complications of surgery, and of C-sections in particular, is infection,\u201d said first author Methodius G. Tuuli, MD, assistant professor of obstetrics and gynecology. \u201cFor a new mother who needs to care for her baby \u2014 which is stressful even when all things are equal \u2014 having an infection can really impair her ability to do that. We are very interested in clarifying the best ways to prevent these infections, reducing the burden on the patients, on their infants and on the health-care system as a whole.\u201d\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release explained that other studies have examined skin-prep, but this one was the first to directly compare dual-element preps for C-sections. Here is an excerpt:\n\u201cPast trials comparing antiseptics before surgery included relatively few participants and often compared a chlorhexidine-alcohol combination with iodine alone. These studies could not determine whether the worse performance of iodine alone was due to the chlorhexidine, the alcohol or the combination.\u201d", "answer": 1}, {"article": "NIAID conducts and supports research \u2014 at NIH, throughout the United States, and worldwide \u2014 to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital. Dr. Nash served as principal investigator of the HALT-MS study.\nIn HALT-MS, researchers tested the safety, efficacy and durability of HDIT/HCT in 24 volunteers aged 26 to 52 years with relapsing-remitting MS who, despite taking clinically available medications, experienced active inflammation, evidenced by frequent severe relapses, and worsened neurological disability.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This news release explains the significance of the study in supporting initiation of a randomized trial. However, the results are not entirely \u201cnew,\u201d as the release states; they were previously reported at a medical conference in June 2016. Also, we found it interesting that the published study states its results are consistent with three similar trials, including this Canadian study, bolstering the validity of its finding. Those trials are not mentioned in the news release.\nThe idea of using bone marrow transplantation for medical illnesses is not new. During the 1990s bone marrow transplantation following high dose chemotherapy was touted as a cure for breast cancer. \u00a0A randomized clinical trial was begun in the late \u201990s but was discontinued when results from the initial studies were found to\u00a0have been fraudulently reported. (Described in a book called \u201cFalse Hope: Bone Marrow\u00a0Transplantation for Breast Cancer\u201d by Peter D. Jacobson and Richard A.\u00a0Rettig.)", "answer": 0}, {"article": "The closed loop insulin delivery system, for example, computes insulin doses and administers them according to glucose levels detected by a sensor. The hope is that an artificial pancreas will closely mimic the way the human pancreas normally releases insulin in response to food or stress.\nThe current study included 24 people with type 1 diabetes and challenged an artificial pancreas prototype in two different real-life scenarios. The first trial was meant to mimic a night of eating at home, while the second trial was designed to simulate an evening out, including drinking alcohol, which can unpredictably lower blood sugar levels.\nAn analysis of pooled data showed that the overall time that plasma glucose levels were in target \"increased by a median 28 percent\" with the artificial pancreas, said the study's lead author Roman Hovorka, a principal research associate at the University of Cambridge in the United Kingdom.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story, like the study, points out that the connection between statin use and renal protection has only been seen in animals. We think the story makes it clear to readers that what\u2019s new and important here is showing a relationship in humans as well.", "answer": 1}, {"article": "And there were other challenges, not the least of which was how to get the siRNAs into the appropriate cell and then make sure they did what they were supposed to do.\nThe precision of the process is crucial to limiting side effects, the researchers said.\n\"This directly interferes with the genetic mechanisms that promote cancer to stop the production of a particular protein,\" added Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. \"This is one step away from getting into the actual DNA.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good job on establishing the novelty of this approach \u2013 and reminding readers that this work lead to a Nobel Prize in 2006 for research in worms \u2013 \"a far cry from humans,\" as the story states. ", "answer": 1}, {"article": "\u2022 The first histologic quantitative analysis of retinal plaque clusters, or \"hot spots,\" containing the most toxic forms of beta-amyloid with specific distribution patterns in superior peripheral regions that were previously unexplored.\nAfter adapting the technology for human application, the researchers initiated several ongoing clinical trials in the United States and Australia to determine the feasibility of detecting and quantifying beta-amyloid plaques in patients with the disease.\nIn the new article, the researchers report on a 16-patient clinical trial to demonstrate the feasibility of identifying beta-amyloid in the eye using autofluorescence imaging. They also provide detailed analyses and several new findings on Alzheimer's pathology in the retina, results of research with donated eyes and brains of 37 deceased patients, 23 with confirmed Alzheimer's disease and 14 controls.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes the novelty of the findings in several areas, noting:\nThe article provides new insights into the disease\u2019s manifestations in the retina and information on the optical imaging system. Here are several highlights:", "answer": 1}, {"article": "While most breast cancer is diagnosed at later ages, about 6% of women learn that they're ill before age 40 - when they are still of childbearing age. Breast cancer treatments that have shown the best results for for disease free survival include chemotherapy, hormonal therapy, or both. For younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility. While many women choose to preserve the option of having children by storing eggs before cancer treatment, the process can be costly and difficult.\nItalian researchers conducted a phase three study that included 281 women with breast cancer, aged 18 to 45 years and who had not experienced menopause. Patients were randomly selected to be treated with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs. The researchers followed the women for one year after they had finished chemotherapy.\nEarly menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients. The results are published in the Journal of the American Medical Association.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes the study as new but fails to indicate whether or not the drug and procedure are new. And as the editorial points out, there are 5 other studies testing this so there is more data out there and it appears to be a bit contradictory.\n", "answer": 0}, {"article": "Because postpartum depression is the most common complication of childbirth, it makes sense to explore peer counseling and other interventions that can reach women in rural or suburban areas where access to mental health professionals may be limited, said Dr. Samantha Meltzer-Brody, director of the perinatal psychiatry program at the Center for Women\u2019s Mood Disorders at the University of North Carolina at Chapel Hill.\n\u201cMost people in the world have access to a telephone,\u201d said Meltzer-Brody, who wasn\u2019t involved in the study. \u201cThis study, while small, suggests that peer phone counseling could be a very effective, widespread public health intervention.\u201d\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story refers to previous studies suggesting the value of peer counseling. It\u2019s clear that this is not the first such study.", "answer": 1}, {"article": "UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK's top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL's associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market. For further information, please visit: http://www. Twitter: @UCL_Business\nProfessor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious. Although detection has been improving, most patients have lost a third of vision by the time they are diagnosed. Now, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma. While we cannot cure the disease, our test means treatment can start before symptoms begin. In the future, the test could also be used to diagnose other neurodegenerative diseases.\"\nInitial clinical trials were carried out on a small number of glaucoma patients and compared with tests on healthy people. The initial clinical trials established the safety of the test for patients.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers to the tool under development as a \u201cpioneering diagnostic.\u201d A researcher is quoted saying, \u201cNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma. While we cannot cure the disease, our test means treatment can start before symptoms begin. In the future, the test could also be used to diagnose other neurodegenerative diseases.\u201d\nWe\u2019ll give the release the benefit of the doubt that the test may potentially be novel for glaucoma but not for any neurological disease for which it hasn\u2019t even been tested.", "answer": 1}, {"article": "The result: by the end of the treatment period, those in the acupuncture group were found to have hot flash scores that were 50 percent lower than those in the non-acupuncture group. The finding continued to hold up for a half-year after the acupuncture sessions ended.\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\nNoting that hot flashes are a fact of life for many women with breast cancer, the investigators found that pairing lifestyle advice with weekly acupuncture sessions dramatically improved the women's quality of life.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is the weakest spot for the story. We found\u00a0three other papers that evaluated acupuncture as a means of addressing hot flashes for cancer patients: this one from 2007, one from 2009, and another from 2009. The findings from the studies are not all in agreement (with each other, or with the study being discussed in this story).\nWhat does it tell us that we didn\u2019t already know? Does it build on previous work? Looking at all of the work on this subject, what do we know about this form of treatment? Those are good questions\u2013important questions\u2013and this story doesn\u2019t address them.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The news hook here is the FDA approval of this drug combination. We\u2019ve already given the story credit for this above under \u201cAvailability.\u201d And we\u2019d note that just because the FDA approves something, doesn\u2019t mean that it\u2019s novel. There are plenty of \u201cme-too\u201d drugs out there, and this story doesn\u2019t make any attempt to clarify how this new drug combination works differently or better than existing drugs.", "answer": 0}, {"article": "Hensrud adds that there are some drawbacks to drinking too much coffee, including liver damage or increased blood pressure. Other possible side effects from drinking a lot of coffee include insomnia, reflux, heartburn, palpitations, urinary systems and increased fluid intake, says Hensrud. He says coffee can also be addictive and some people may suffer from withdrawal headaches. Too much coffee may make it harder to conceive and can increase the risk of miscarriage.\nWhile these results are encouraging, it doesn't mean we should just go out and start drinking lots of coffee, says Mia Hashibe, lead researcher and an assistant professor in the department of family and preventive medicine at the University of Utah.\nIt\u2019s not exactly known why coffee may help prevent these cancers. But coffee contains over 1,000 different chemical compounds, including cancer-fighting antioxidants, and it\u2019s those antioxidants that may provide a \u201cplausible explanation\u201d for reducing the cancer risk, says Hensrud.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least briefly mentions other coffee research: \"Other recent studies suggest coffee may have beneficial effects in other diseases like dementia, diabetes, liver and Parkinson\u2019s disease. However, coffee alone may not be the answer according to some experts.\"", "answer": 1}, {"article": "Psoriasis is a condition that affects 7.5 million Americans, according to the National Psoriasis Foundation. It is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime. Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin. Psoriatic arthritis is similar in presentation -- but also can lead to joint pain.\nThe researchers say excess weight loss may reduce the body-wide inflammation and pain triggered by extreme excesses of fat tissue. They plan to present their findings on Sunday Nov. 8, 2015 at the 2015 ACR/ARHP Annual Meeting in San Francisco.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity. Patients who saw the most improvements had more severe disease at the time of surgery and were of an older age at diagnosis.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "One could easily come away from this release thinking that these researchers are the first to report psoriasis symptom reduction in those undergoing bariatric surgery (with resultant weight loss). However, such findings have been reported before, and the release does not acknowledge this.", "answer": 0}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people. It damages the center of the retina, or macula, and results in a loss of vision in the center of the visual field. There are two forms of AMD, a wet form and a dry form.\n\"This is truly a breakthrough technology for AMD patients as their treatment options have been limited until now,\" says Kathryn A. Colby, MD, PhD, an ophthalmic surgeon at the Massachusetts Eye and Ear Infirmary in Boston and an assistant professor of ophthalmology at Harvard Medical School.\n\"This innovation has the potential to provide many people with an improved quality of life,\" Jeffrey Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health, says in the news release.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of this approach and the void it would fill in treatment is explained. ", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear that the procedure has been in use for decades. What could have used more exploration\u2013from independent sources\u2013is whether it\u2019s overused.", "answer": 1}, {"article": "April 21, 2010 -- An experimental oral drug is showing early promise for the treatment of chronic hepatitis C virus (HCV) infection, a study shows.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that there are many other drugs being developed to treat hepatitis C. It explained that a potentially novel advantage of the new compound is that it seems to be effective against all genotypes.", "answer": 1}, {"article": "June 11, 2012 (Philadelphia) -- In an early study, an experimental stem cell procedure helped 15 teens with type 1 diabetes stay off of insulin injections for about 1.5 years, on average.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\nIn the new study, 15 of 28 teens with type 1 diabetes who got an experimental treatment using their own stem cells went into remission and did not need insulin injections for an average of about 1.5 years.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story acknowledged that other stem cell studies showed promising results for Type 1 diabetes.", "answer": 1}, {"article": "\"It was the most amazing and grace-filled experience to finally have that moment of having my baby be placed on my chest,\" Caminiti says. \"He was screaming and then I remember that when I started to talk to him he stopped. It was awesome.\"\n\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.' A lot of women felt like they failed because they couldn't do a vaginal delivery,\" says Snow.\nSo why has the procedure been slow to catch on? Hospitals aren't charging more for it \u2014 so cost doesn't seem to be a major factor. What's lacking are clinical studies. Without hard scientific data on outcomes and other concerns like infection control, many hospitals may be wary of changing their routines. Betsey Snow of Anne Arundel Medical Center says the family-centered C-section represents a cultural shift, and her hospital is helping break new ground by adopting it.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The piece presented the family-centered cesarean as a \u201crelatively new idea in the US\u201d and mentioned that it has been \u201cslow to catch on.\u201d But media outlets have been writing about it since London-based professor NM Fisk wrote about the idea in 2008 in the journal BJOG. Brigham and Women\u2019s Hospital in Boston also released a press report in June 2013.\nAlthough the phrase \u201crelatively new\u201d is vague, we think it\u2019s enough for a satisfactory rating.", "answer": 1}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that both low-carb and low-fat diets are proven to produce weight loss. However, it suggests that we should be surprised that a low-carbohydrate diet could produce such beneficial effects on blood pressure.\u00a0In fact, this effect was well-documented in another comparison\u00a0of weight loss diets\u00a0published in JAMA in 2007.", "answer": 0}, {"article": "In the area of sexual dysfunction, it may be the woman\u2019s turn for a break-through.\nMichael Sand, director of clinical research at Boehringer, said the company intends to pursue regulatory approval based on the late-stage study findings. It could take two to three years to come to market in the United States, the company said.\nA once-a-day drug being developed to treat women with low libido proved to boost desire and led to better sex among female patients participating in late-stage studies, according to publications presented today during a medical meeting in Lyon, France.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This story is accurate in stating that\u00a0if approved, flibanserin would be the first drug of its kind for pre-menopausal women.\u00a0 It does acknowledge that\u00a0other efforts to produce a similar drug have been unsuccessful. ", "answer": 1}, {"article": "HCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\nWhile Rimer said the research established the groundwork to design an effective drug, questions remain. Long-term safety, dosage and additional human trials are needed, he said.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote. \"HCA may be preferred as a therapy over CA (potassium citrate).\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There do not appear to be any other studies available on www.PubMed.gov that look at hydroxycitrate as a potential kidney stone treatment.", "answer": 1}, {"article": "In the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nGuallar and his colleagues wanted to look specifically at the link between selenium and cholesterol. They recruited about 500 older adults in the UK to take one of three different doses of selenium daily \u2014 100, 200, or 300 micrograms \u2014 or a placebo pill with no selenium.\nThe finding \u201cis not generalizable to other patients,\u201d he said. \u201cIn a population like the U.S. where selenium levels are adequate, there\u2019s no reason to take extra selenium in supplements.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story acknowledges previous research that had linked high selenium with higher cholesterol levels.", "answer": 1}, {"article": "Medical device makers have been working for years to develop a so-called artificial pancreas to deliver insulin to patients with type 1 diabetes, an autoimmune disease in which the body destroys its own ability to make insulin.\n\u201cThese devices could transform the management of type 1 diabetes, but it is likely to be a gradual process,\u201d Roman Hovorka of Cambridge, who led the research, said in a telephone interview.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that medical device makers have been working for years to develop a so-called artificial pancreas.\u00a0While this is perhaps enough to satisfy the criterion, the story\u00a0could have\u00a0mentioned\u00a0that some of the most important features that an \"artificial pancreas\" might provide\u00a0can already be found on commercially available products. A Medtronic Insulin pump can suspend insulin delivery when\u00a0it\u00a0gets a low blood glucose reading from the continuous glucose monitor to prevent hypoglycemia. This pump is not available in the U.S. because it doesn\u2019t have regulatory approval\u2013something that is also likely to take\u00a0a long time for an \"artifical\u00a0pancreas.\" \u00a0\u00a0\u00a0", "answer": 1}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story establish the true novelty of the approach?", "explanation": "We readily admit that we\u2019re holding the story to a high standard here, but we do so unapologetically. In the context of a news story, any time something is not specifically labeled as \u201cnot new,\u201d readers will likely infer that it is new.\u00a0However, this technology has been around for quite some time, and the story doesn\u2019t really establish that fact. The story does note that the study funded by a device manufacturer dates back to 2005. But it wasn\u2019t new even then. For example, California\u2019s Department of Health Services issued an updated(!) fact sheet on the health hazards of these devices in January of 1998. Establishing that back story would\u2019ve clued readers in to the fact that we\u2019ve seen this movie before.", "answer": 0}, {"article": "\u2022 One or two weekly strength training sessions using weights or exercise machines were included on a separate day, or after an endurance session.\nIn the current study, researchers wanted to know if exercise can restore the heart's elasticity in previously sedentary individuals - especially if begun in late middle age. Previous studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\nTo reap the most benefit, the exercise regimen should begin by late middle age (before age 65), when the heart apparently retains some plasticity and ability to remodel itself, according to the findings by researchers at the Institute for Exercise and Environmental Medicine (IEEM), which is a collaboration between UT Southwestern Medical Center and Texas Health Presbyterian Hospital Dallas.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release mentions early research by cardiologists from the same institution documenting stiff left ventricles in middle-aged people who don\u2019t exercise. It\u2019s mentioned that this study is unique in asking the question: can exercise restore heart elasticity in previously sedentary, middle-aged people?\nWe\u2019ll rate this satisfactory. But really, this is just one of innumerable studies that show exercise is beneficial. It might be measuring the benefit in a novel way but, in the end, it is just suggesting that exercise is good.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Physicians have treated Parkinson\u2019s patients with the drugs pergolide and cabergoline for a long time. The news article accurately represents their controversial history, though it neglects to note that other medicines in this drug class are avaliable that do not appear to cause heart valve disease.", "answer": 1}, {"article": "Dr. Smith does not advocate that strategy, saying that the stool test can have false positives from things like red meat or broccoli that have nothing to do with colon cancer. He worries that frequent stool tests will lead to frequent false alarms and frequent colonoscopies without making much of a dent in the colon cancer death rate.\nNow, researchers say, the challenge is to find out why the test missed so many cancers, in particular, those on the right side of the colon, and whether the problem can be fixed.\nOne solution, supported by six studies, is to be sure there is just a short time between when patients finish taking the strong laxative that cleanses their bowel and the colonoscopy, Dr. Rex said. That usually means taking half of the laxative the night before the screening test and the rest in the morning, something that often is not done, he added, but that he and others recommend.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly colonoscopy is not a new idea.", "answer": 1}, {"article": "\"The current study demonstrated that weekly injections of CAM2038 produced significant and robust opioid blockade, a critical mechanism of efficacy for medications treating opioid dependence. CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\n\"This study provides clinical proof of concept that CAM2038 will be an effective treatment for opioid use disorder,\" said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals, \"The current opioid crisis demands innovation, and CAM2038's novel technology is now one step closer to providing physicians and patients with a different approach to treating this deadly chronic disease.\"\n\"The study results show that CAM2038 provides rapid and extended blockade of opioid effects,\" said Fredrik Tiberg, President and CEO of Camurus. \"The results also confirm the dose selection in the current Phase 3 program and the potential of CAM2038 as a future treatment alternative for patients with opioid use disorder, from initiation to long-term maintenance.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests the product under development is \u201cnovel\u201d and that it \u201chas the potential to alter the current treatment paradigm for opioid dependence.\u201d We aren\u2019t really told what is novel about the formula, though. A weekly or monthly administered opiate antagonist would be a new addition to the treatment options but it is not really novel.", "answer": 0}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story establish the true novelty of the approach?", "explanation": "We\u2019re only told that this is a new device, newly approved by the FDA. \u00a0But its unique place in the treatment of this brain tumor type is not clearly defined. In reality, the use of weak electrical fields to interrupt cancer cell growth has been known for some time. But we\u2019re not given any of that context.", "answer": 0}, {"article": "Open conditions were slightly cooler than closed, although humidity levels were similar across settings, according to the report in the journal Indoor Air.\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\n\u201cSleep quality is affected by many factors, such as health and emotional states, bedding conditions and different environmental conditions, including noise levels and temperature,\u201d said Dr. Nuno Canha of the University of Lisbon in Portugal. Canha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns. He is also part of LIFE Index-Air, a European research group that focuses on human exposure to pollutants.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish what makes this research novel. It\u2019s fairly well-known that indoor air quality can be poor, and that ventilation can help circulate the air.", "answer": 0}, {"article": "\"These include reducing inflammatory responses, increasing micronutrients, improving vitamin and mineral imbalances, changing lipid profiles by using olive oils as the main source of dietary fats, maintaining weight and potentially reducing obesity, improving polyphenols in the blood, improving cellular energy metabolism and maybe changing the gut micro-biota, although this has not been examined to a larger extent yet.\"\nLeading author Roy Hardman from the Centre for Human Psychopharmacology Swinburne University of Technology Melbourne Australia and his colleagues evaluated all the available papers between 2000-2015 that investigated if and how a MedDiet may impact cognitive processes over time. In total, 18 out of the 135 articles met their strict inclusion criteria.\nBy sticking to the Mediterranean diet the study showed that people had slowed rates of cognitive decline, reduced conversion to Alzheimer's, and improved cognitive function.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Studies of this diet are numerous. Although this meta-analysis may be unique in its analytical characteristics, the text makes no claim for novelty.\nThe release includes quotes which make the study sound like new information, when it really isn\u2019t. For example:\n\u201cThe most surprising result was that the positive effects were found in countries around the whole world. So regardless of being located outside of what is considered the Mediterranean region, the positive cognitive effects of a higher adherence to a MedDiet were similar in all evaluated papers.\u201d", "answer": 0}, {"article": "No, she\u2019s not RoboCop or Darth Vader. But she shares a similarity with those characters: Her all-too-human body has been upgraded with a machine.\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive. Jay says she was lucky: Her insurance covered much of the six-figure bill for the procedure.\nIn an article on Popular Science\u2019s website, Jay writes about her experience with pain and the next-generation way she\u2019s finding relief.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Spinal cord stimulation appears to have been around for years, though the marketing of these devices appears to be on the upswing. One concern: The piece refers to her getting a \u201cnext generation stimulator. This implies that there is a prior generation one, and we\u2019re not sure what the difference is.", "answer": 1}, {"article": "\u2022 A plant-based vegetarian diet is not associated with statistically significant changes in triglyceride levels in observational studies or in clinical trials.\nThe authors predict the strong correlation between vegetarian diets and lower cholesterol levels may be due to the association a plant-based diet has with a lower body weight, a reduced intake of saturated fat, and an increased intake of plant foods, like vegetables, fruits, legumes, nuts, and whole grains, which are naturally rich in components such as soluble fiber, soy protein, and plant sterols.\nThe study authors hypothesize that the greater risk reduction for total, HDL, and LDL cholesterol levels observed in the longitudinal studies is likely due to long-term adherence to plant-based eating patterns and changes in body composition.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Is it novel to show that vegetarian diets are associated with lower cholesterol? Other studies have examined the relationship between vegetarian diets and plasma lipid levels, and comparing them with omnivorous diets, found there was no difference in high density lipoprotein cholesterol (HDL-c).\nWe wondered if there was some other aspect of the study that made it novel. The release notes that the study goal was to examine the association between a vegetarian diet and plasma lipid levels \u201cthroughout the lifespan.\u201d According to the published study, this was the first meta-analysis to do so on a \u201clong-term\u201d basis. However, to be included in the analysis, clinical trials and observational studies only had to be 4 weeks of duration \u2014 hardly \u201clong-term.\u201d\n\u00a0", "answer": 0}, {"article": "Marban and his wife, Linda, are founders of a company that has filed patents for the techniques.\nThe researchers found that magnetism attracted the stem cells to injured areas, tripling the retention rate in the heart.\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said. \"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "No context given on other research to enhance cardiac stem cell interventions. ", "answer": 0}, {"article": "More recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years. And new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur. \u201cTruly phenomenal early results,\u201d Dr. Herrmann said.\n\u201cThis technology is expensive and high risk,\u201d Dr. Mack said. The consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\nThat, said Dr. Leon of Columbia, who was the trial\u2019s principal investigator, was remarkable. \u201cIf we treat five patients, we would save a life in the first year,\u201d he said. \u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is described nicely \u2014 the article goes into depth on the history of the device.", "answer": 1}, {"article": "Dieters who go vegetarian not only lose weight more effectively than those on conventional low-calorie diets but also improve their metabolism by reducing muscle fat, a new study published in the Journal of the American College of Nutrition has found.\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nDr. Kahleov\u00e1 said: \"Vegetarian diets proved to be the most effective diets for weight loss. However, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism. This finding is important for people who are trying to lose weight, including those suffering from metabolic syndrome and/or type 2 diabetes. But it is also relevant to anyone who takes their weight management seriously and wants to stay lean and healthy.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release describes what the study set out to do \u2014 measure changes in weight and in subfascial and intramuscular fat and how these change can impact metabolism. But the study isn\u2019t novel. Numerous studies have been conducted on the effects vegetarian diets have on different types of body fat as well as weight and metabolism.", "answer": 0}, {"article": "Thrombectomy involves a catheter placed in the femoral artery and snaked up the aorta and into the cerebral arteries where the clot that is blocking the artery, and causing the neurological symptoms, is retrieved.\nTo select patients for the trial, the researchers used a new approach which used brain imaging and clinical criteria as opposed to just time alone.\nThe DAWN trial included trial locations in the United States, Spain, France, Australia and Canada. The trial was sponsored by Stryker Corporation, a medical technology company that manufactures the clot removal devices used in the study.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release might have noted that previous research had suggested that some extension of the six-hour timetable for optimal clot removal was possible, even for medical therapy. But overall, the release makes clear why and how this trial was novel.", "answer": 1}, {"article": "In fact, as a Federal Register posting last year chronicled, there have been questions raised about whether 17-HP caused birth defects of various kinds. In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects. They later revoked them.\nFleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES. In 1971 researchers realized children exposed to DES in utero had a higher incidence of vaginal and breast cancers, and males were subsequently found to have urinary-tract problems.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Good historical context, explaining that \u201cInterestingly, the drug is not new \u2014 it\u2019s just taken a long and circuitous route to approval.\u201d", "answer": 1}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The column did a solid job summarizing the current status of research in this field.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes how the new tests wed radioactive tracing materials with an amino acid (in the case\u00a0of the prostate cancer) and other molecules, and sufficiently explains how the new tests differ from current nuclear images.", "answer": 1}, {"article": "Structured clinical interviews, such as the Hamilton Depression Rating Scale and the Hamilton Anxiety Rating Scale, and patient questionnaires, like the Beck Depression Inventory and the State-Trait Anxiety Inventory, assessed depression and anxiety. Other questionnaires assessed quality of life, death acceptance, meaningful existence, optimism and spirituality -- generally defined as a search for the meaning of life and a connection to something bigger than one's self. To measure the changes in attitudes, moods and behavior over time, the researchers administered a questionnaire that assessed negative or positive changes in attitudes about life, mood and behavior.\nThe Johns Hopkins team released its study results, involving 51 adult patients, concurrently with researchers from New York University Langone Medical Center, who conducted a similarly designed study on 29 participants. Both studies are published in the Journal of Psychopharmacology on Dec. 1.\n\"Before beginning the study, it wasn't clear to me that this treatment would be helpful, since cancer patients may experience profound hopelessness in response to their diagnosis, which is often followed by multiple surgeries and prolonged chemotherapy,\" says Griffiths. \"I could imagine that cancer patients would receive psilocybin, look into the existential void and come out even more fearful. However, the positive changes in attitudes, moods and behavior that we documented in healthy volunteers were replicated in cancer patients.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release places the work in the context of previous research from Johns Hopkins, which is enough \u2014 barely \u2014 to earn it a satisfactory rating here. What we would really like to see is how this work compares to previous research done specifically on the use of psilocybin to treat anxiety in cancer patients \u2014 such as this 2007 study, this one from 2011, or this one from 2013. We don\u2019t necessarily expect an exhaustive comparison, but there needs to be at least some recognition that other work has been done in this field over the past 10 years.", "answer": 1}, {"article": "Yet the study suggests the opposite has happened. From 2001 to 2013, co-prescriptions to opioids and benzodiazepines among the studied pool of patients increased from 9 percent to 17 percent \u2014 a nearly 89 percent jump.\nGiven that the opioid epidemic has quickly turned into the deadliest drug crisis in US history, it\u2019s important \u2014 and potentially lifesaving \u2014 for doctors and policymakers to at least consider the study\u2019s findings.\nA new study published in BMJ looked at just how much the concurrent use of these two drugs increases the risk of overdose versus the risk of only using opioids. Drawing on a huge sample of nearly 320,000 patients who were continuously enrolled in private health insurance plans from 2001 and 2013, researchers compared those who were prescribed just opioids versus those who were prescribed both, and what their additional risk of an emergency room visit or inpatient admission was in the period they were prescribed both.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says researchers \u201cjust uncovered\u201d the danger of tandem opiod/benzodiazepine use and quotes a researcher saying the study \u201creveals an underappreciated policy lever for reducing drug overdoses: Making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\u201d\nIn fact, this has been the radar of the medical community for awhile. A 2015 study found veterans using opioids had a higher risk of death from drug overdose if they also used benzodiazepines. And last year two government agencies took action: The U.S. Centers for Disease Control and Prevention amended guidelines to discourage clinicians from prescribing both types of drugs simultaneously, while the FDA advised of the dangers of mixing the drugs and strengthened warning labels and patient medication guides for nearly 400 products.\nInstead, the challenge has been figuring out how to get patients off of this drug combination and recent\u00a0research/care delivery redesign efforts are tackling this issue (but this article doesn\u2019t not get into this at all, nor is this what the research study is about).", "answer": 0}, {"article": "NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc\u2019s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.\nAn analysis of data combined over multiple U.S. health plans showed approximately 50 percent of patients discontinue oral bisphosphonate therapy within the first year, Amgen said.\n\u201cI believe it will have gradual uptake in the commercial setting given that this is a silent disease and existing therapies are pretty good,\u201d Schmidt said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "\u2022 Prostate cancer is one of the leading causes of death among men.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type. This could lead to a better quality of life and more effective treatment based on which prostate cancer a man is diagnosed with.\n\"If five types of the disease exist, how does this change popular medical opinion on prostate cancer screening? This may mean that each type of the disease needs its own approach to screening, diagnosis, treatment and even recurrence,\" noted Dr. Samadi.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The findings reported in the study seem to be newsworthy, and we\u2019ll give credit\u00a0for indicating that \u201cnew research has revealed\u201d and \u201cthis discovery\u201d as\u00a0establishing novelty. There\u2019s also a nod to previous research about prostate cancer genetics.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology. ASA is committed to ensuring physician anesthesiologists evaluate and supervise the medical care of patients before, during and after surgery to provide the highest quality and safest care every patient deserves.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\n\u201cLabor pain matters more than just for the birth experience. It may be psychologically harmful for some women and play a significant role in the development of postpartum depression,\u201d said Grace Lim, M.D., director of obstetric anesthesiology at Magee Women\u2019s Hospital of the University of Pittsburgh Medical Center and lead investigator on the study. \u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "While technically a novel result, it\u2019s a minor one. We found a 2014 study in Anesthesia & Analgesia that explored the same question, though in a Chinese population and with greater rigor. That study compared women who chose epidurals to those who chose a \u201cnatural\u201d birth without epidurals. Interestingly, we found a 2015 commentary that responds to this 2014 study \u2014 and it was authored by Lim (the lead author of the new study), who rightfully states that, if epidurals do decrease the risk for postpartum depression, then \u201cit could have tremendous ramifications on the long-term mental well-being of half of the world\u2019s population who are of child-bearing age.\u201d Lim\u2019s letter also called for more research with larger sample sizes to try and replicate the results. But roughly one year later, Lim\u2019s abstract explores the question with no overt controls and a similar sample size.", "answer": 0}, {"article": "In the top three most effective formulations of ECP, 90.6% (29 of 32) of patients had a rating of excellent or good. With ColonaryConcepts' lead formulation, 93.3% (14 of 15) of patients had a rating of excellent or good, with 40 of 45 colon segments rated as excellent or good on the Ottawa scale. For the comparator products, 85.7% (12 of 14) had a rating of excellent or good. There were no serious adverse events across any of the treatment groups. The proportion of patients reporting being satisfied or extremely satisfied with the experience of using the lead ECP formulation was nearly double that for those using the standard preps, 64.3% versus 33.3%.\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\nResults from the randomized, single-blind study will be presented today at the American College of Gastroenterology 2016 Annual Scientific Meeting, being held in Las Vegas, NV, by principal investigator, Douglas K. Rex, M.D., Distinguished Professor of Medicine, Indiana University School of Medicine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release uses the term \u201cnovel\u201d to describe this new prep formulation. \u00a0Although a variety of preps are now available, this study\u2019s novelty appears to be its high level of patient satisfaction.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story establish the true novelty of the approach?", "explanation": "What appears to be \u201cnew\u201d is the explosion of combing salons and newer prescription shampoos, as well as the review article published last week that evaluates them.", "answer": 1}, {"article": "Of course, there are other benefits to more frequent and more intense bouts of exercise. Both the American Heart Association and the World Health Organization recommend getting at least 150 minutes of moderate- to high-intensity physical activity a week for cardiovascular and overall health.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey. \u201cOur study takes this a bit further and shows that exercise may also have a role in preventing people developing depression in the first place.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Exercise for mental health is not a new concept. What makes this study novel is that it\u2019s looking at exercise\u2019s potential to prevent depression, and if that impact would be useful enough for a public health level initiative. As the study explains:\n\u201cWhile many agencies are keen to promote the potential mental health benefits of exercise, at present the literature is unable to provide the most basic information needed for effective, targeted, evidence-based public health campaigns concerning depression and anxiety.\u201d\nThe story didn\u2019t explain this.", "answer": 0}, {"article": "The most common side effects were sleepiness (reported by about 10 percent of patients on the two higher doses of suvorexant), headache (reported by about 5 percent), dizziness and abnormal dreams (5 percent).\nThe study, published online Nov. 28 and in the Dec. 4 print issue of the journal Neurology, included 254 healthy adults with primary insomnia, which means it wasn't caused by an underlying physical or mental health problem.\nOverall, Herring's team found, people slept better with the drug, although the improvement was not dramatic.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "One of the independent experts addressed the drug\u2019s relative novelty in this section:\n\u201csuvorexant is seen as a potentially important development in the world of sleep medicine, because the drug blocks specific brain chemicals called orexins, which help keep people awake. Standard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\n\u201cThe way [suvorexant] works makes a lot of sense,\u201d Bazil said. \u201cThe hope is that it will help some people who haven\u2019t responded to [other drugs], and have fewer side effects.\u201d", "answer": 1}, {"article": "Suboxone works by taking the place of the opioids in the receptor - not only shutting off withdrawal symptoms but also blocking the effects of any new drugs.\nPatients in the trial are given counseling as well as a new kind of anti-addiction drug called Suboxone. It's an orange pill that's dissolved under the tongue.\n\"I didn't want to wake up every morning and chop up OxyContin, sniff it again during the day. I mean, that's a terrible way of life,\" he said. \"The Suboxone got me far enough away to look and say 'wow, look at your life. Let's address what's going on.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment in places implies the drug is new and novel (by referring to the current clinical trial, by using the word \"new\" to describe it, and by emphasizing its hope for revolutionalizing treatment). But it also states that it is currently available. This leaves the viewer uncertain about what\u2019s \"new\" here.\nSo what is new? Buprenorphine has been an approved parenteral analgesic for decades. The drug was approved in 2002 as an alternative to methadone\u2013a drug to be taken as a more benign replacement for the more addicting drug being abused, such as heroin. It enables withdrawal from the addicitive drug, which may be followed by other addiction treatments or maintenance therapy.\u00a0 \nThe current trial involves only patients who are addicted to painkiller medications like OxyContin. The study is designed to determine whether those taking Suboxone and getting supportive counseling can taper off Suboxone fairly quickly and become entirely drug-free.\u00a0\u00a0 ", "answer": 0}, {"article": "6) Reporting a relatively minor stressor each day, then listing ways in which the event can be positively reappraised. This can lead to increased positive affect in the face of stress \nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV. Based on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\nFor the HIV study, which was based in San Francisco, 80 participants (primarily men) were taught a set of eight skills over five weekly sessions to help them experience more positive emotions. Another 79 participants were in the control group.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release contains this claim of novelty:\n\u201cThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV. Based on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\u201d\nWe believe others in medicine have probably used \u201cpositive\u201d intervention before, but they may have called it support or emotional coaching or many other phrases. Cognitive-behavioral therapy, massage, and other means to improve a person\u2019s coping skills could be considered \u201cpositive emotion intervention.\u201d", "answer": 0}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day. \u201cWhen the hunger comes back, the topiramate kicks in,\u201d says study author Suzanne Oparil, MD, a professor of medicine, physiology, and biophysics and director of the vascular biology and hypertension program at the University of Alabama at Birmingham. Topiramate also has blood pressure-lowering effects, she says. Oparil is a consultant for Qnexa manufacturer Vivus.\nThe new analysis of three separate studies included more than 4,500 people. Researchers compared several doses of the new pill with placebo among severely obese adults, as well as overweight, nonobese people who had other health problems related to their weight, such as high blood pressure or metabolic syndrome, a cluster of risk factors that increase risk for diabetes and heart disease.\nOverall, people who took the combination pill lost more weight than their counterparts who were given a placebo. The higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story reported that the drug was a combination of two commercially available medications. \u00a0", "answer": 1}, {"article": "Then they looked at the results of each patient's colonoscopy. The study found that patients classified under the scoring system as low-risk did, in fact, have far fewer advanced abnormal growths that might develop into cancer, compared to patients classified as high-risk.\nImperiale's team noted that not all people deemed to be at \"average risk\" for colon cancer face the same risk of the disease, and so some might benefit more from invasive colonoscopy than others.\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it sound as if this is a first-of-its-kind tool. However, risk calculation tools for colon cancer have been in circulation for many years.", "answer": 0}, {"article": "March 11, 2010 (Miami Beach, Fla.) -- A moisturizing cream whose active ingredient is extract of onion can help take the redness out of new stretch marks. New stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD. \"But [after several weeks of treatment], the cream made them look and feel better,\" she says. The study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology. Draelos has served as a consultant to Merz.\n\nDraelos estimates that up to 98% of women and 75% of men have stretch marks, which appear as wavy, linear red scars, typically on the hips, breasts, thighs, and stomach of women, and the buttocks and pectoralarea of men. They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt. Sinai Medical Center in New York City. He was not involved with the research. \"Unfortunately, stretch marks are permanent. Exercise and diet won't help,\" he says. They're not harmful to your health, but many people are bothered by their appearance. The marks slowly fade and become flat on their own, but that can take years. As a result, doctors have been looking for a product to make new stretch marks look and feel better, Draelos says.\n\nAny insult to the skin -- be it a cut or wound or the rapid stretching that drives the formation of stretch marks -- is accompanied by inflammation. Onions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says. The new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says. And it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.", "question": "Does the story establish the true novelty of the approach?", "explanation": "There are many creams that combine moisturizers and plant extracts and claim to treat skin problems.\u00a0This story should have challenged the notion that adding\u00a0onion extract to a skin\u00a0cream makes it\u00a0in any way \"new.\" \u00a0\u00a0\u00a0", "answer": 0}, {"article": "UVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example. \u201cNo matter how well you sterilize a room beforehand, the medical staff can still bring in dangerous bacteria like MRSA,\u201d says Brenner. \u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\u201cWe\u2019ve known for a century that UV light is extremely efficient at killing microbes, bacteria, and viruses,\u201d says study leader David Brenner, director of the Center for Radiological Research at Columbia University Irving Medical Center. For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\nBrenner says his team is working with a company to develop a commercially available version of the lamp, which could become a cost-effective way to battle flu epidemics on a population level. \u201cThe lamp we\u2019re using at the moment costs less than $1,000, and you can imagine that if it were put into general circulation, the price would drop dramatically,\u201d he says. \u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It is made clear the authors have studied this type of light in killing methicillin-resistant staph. aureus (MRSA), but it\u2019s not clear if the current study is the first to apply far-UVC light to an influenza virus (in the published study the authors claim this is the first time far-UVC light has been assessed for inactivating aerosolized viruses).", "answer": 0}, {"article": "PCA3 is found only in the prostate. When prostate cells become cancerous, their PCA3 genes go crazy. Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe PCA3 test isn\u2019t a replacement for PSA testing. But it improves the ability to diagnose prostate cancer, Groskopf says.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0This story failed to mention that peer reviewed studies examining the utility of PCA3 have not found it to be significantly associated with progression of prostate cancer.\u00a0 Reporting on the results of this recent study, based on information from a company spokesperson without examining what others may have found to date is inadequate.\n", "answer": 0}, {"article": "For patients who have already received ceramic hips that have started to squeak, many orthopedic surgeons advise nothing more than watchful waiting unless there are also signs that the hip is slipping out of place or that ceramic particles are breaking loose from the head or the socket. Doctors who have removed ceramic hips say they find dark stripes that indicate accelerated wear on the ceramic heads. But durability tests have suggested that even those extracted hips would have outlasted conventional metal-and-plastic replacement joints, according to researchers.\nAlready, dozens of patients have elected to endure subsequent surgeries to replace the noisy hips. Some have sued Stryker, the pioneer and market leader, which some doctors say has been slow to take their patients\u2019 concerns seriously.\nDr. D\u2019Antonio, whose longstanding role in Stryker\u2019s product development efforts earned him $1.1 million in consulting payments from the company last year, said he had implanted 400 Tridents since the clinical trials began in 1996. He said that only four of his patients had noticed squeaks and that none of them were able to reproduce them in his office.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that Stryker introduced ceramic hip implants into the U.S. in 2003.", "answer": 1}, {"article": "Each year, prostate cancer is diagnosed in more than 218,000 U.S. men. About 28,000 die of it, making it the most common cancer and second-leading cancer killer among men.\n\"The benefit of screening at this time is uncertain, and if there is a benefit, it's likely to be small,\" said Ned Calonge, who chairs the 16-member U.S. Preventive Services Task Force. It published the new guidelines today in the Annals of Internal Medicine. \"And on the other side, the risks are large and dramatic.\"\nThe task force and other groups concluded previously that it was unclear whether the benefits of the prostate-specific antigen, or PSA, test outweigh the risks. The new review of the scientific literature found no evidence to alter that assessment for younger men. It did find enough new data to recommend for the first time against screening for older men.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was reporting on the release of new guidelines from the US Preventive Services task force, and highlighted that these recommendations differ from the previous version in that they specify that the benefit of routine screening of men older than 75 years of age for prostate cancer is little to none while at the same time, the harms are moderate-to-substantial.", "answer": 1}, {"article": "The pilot trial was funded by the Rotary Club in Bristol who held annual Run for the Future events in Bristol.\nThe research team is now looking to fund a full clinical trial.\nProfessor Chris Probert from the University of Liverpool's Institute of Translational Medicine began work on this project with UWE Bristol when he was working in Bristol as a gastroenterologist with clinical and research interest in inflammatory bowel disease.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The device is similar to many other technologies in development that are said to \u201csniff\u201d cancer based on specific odor signatures. But the release makes it sound as though this device is unique.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that Pap smears rely on using a microscope to hunt for cancer cells, whereas the newer methods described use genetic testing. The story also notes how ultrasound and genetic blood tests for uterine cancers typically are used only when symptoms arise \u2014 an advanced stage of the cancers \u2014 since the those tests \u201cfail to detect many cancers, and also send up a lot of false alarms.\u201d The article places extra emphasis on so-called \u201cliquid biopsies,\u201d saying thy \u201chold the promise of revolutionizing cancer screening\u201d due to a lack of early screenings for these cancers. (That remains to be seen.)", "answer": 1}, {"article": "Dec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\n\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD. \"But we think these results are as good as we've ever seen is such a refractory [sick] population,\" he says.\nThe findings were presented at the San Antonio Breast Cancer Symposium.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes the novelty of the compound as a combination of an existing drug and a derivation of an older, abandoned drug. It also describes that there are other ongoing studies of T-DM1.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does state that the new recommendations represent a departure from existing guidelines.", "answer": 1}, {"article": "NEW YORK April 25, 2018 - A new method for early and accurate breast cancer screening has been developed by researchers at Ben-Gurion University of the Negev and Soroka University Medical Center, using commercially available technology.\n\"We've now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages,\" says Prof. Zeiri. \"With further study, it may also be possible to analyze exhaled breath and urine samples to identify other cancer types, as well.\"\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release does not make clear that urine and breath tests have existed and been used for breast cancer, but the novel part of this study is the statistical analysis and modeling.", "answer": 0}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nDr. Christine Berg, one of the leaders of the U.S. screening studies, said that generally about a quarter of chest CT scans show some kind of abnormality \u2014 but 96 percent of those abnormal scans turn out not to be lung cancer. While doctors ruled out cancer, those patients would have undergone further tests, sometimes including biopsies, which can cause complications including infection and bleeding.\nFive years after their diagnosis, 95 percent of people whose cancers were found through a CT scan were still alive, compared to 73 percent diagnosed with an X-ray and 40 percent of patients who had not been screened and whose symptoms led to discovery their disease.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story put the new study in the context of other research in this field.", "answer": 1}, {"article": "In both breast and other cancer trials, palbociclib has been shown to be safe with once-daily dosing, and its main adverse effect is reversible neutropenia, an abnormally low count of neutrophils, a type of white blood cell that helps fight infections. The lower their neutrophil count, the more vulnerable patients are to infectious diseases. In such cases the drug is temporarily discontinued and reintroduced at a lower dose. Other side effects included fatigue (33 percent), nausea (30 percent), diarrhea (18 percent), constipation (12 percent), and rash (12 percent).\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn. These tools can help to individualize patient therapy going forward.\n\"This drug has minor effects on normal cells other than neutrophils (white blood cells),\" said the study's senior author, Peter J. O'Dwyer, MD, a professor of Hematology/Oncology at Penn and director of the Developmental Therapeutics Program at the ACC. \"In tumors, it can cause shrinkage, or more commonly, arrest of growth. As we discover new functions for the CDK4/6 target of this medicine, we are likely to use it in combinations to make other anti-cancer agents work better.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The drug is the first of a new class of drugs and that\u2019s noted in the release. ", "answer": 1}, {"article": "And research presented at meetings isn't subjected to the same level of scrutiny as studies published in peer-reviewed journals.\n\"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure,\" study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.\nFor this phase 2 study, 39 patients with advanced heart failure were randomly chosen to receive either the gene therapy (through cardiac catheterization) or a placebo.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThis gene therapy technique is indeed something new, but the story would have been better if it had included some independent assessment of a researcher\u2019s claim that, \u201cThis is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure.\u201d \nAlso, the researchers reported very similar results at other heart failure meetings last summer. The story does not make clear that this latest announcement merely adds a few more months of follow-up, not entirely new results.", "answer": 1}, {"article": "As a result, federal health officials have recommended that women bothered by menopausal symptoms such as unpredictable sweats, sleep disturbances and vaginal dryness take the lowest dose of estrogen for the shortest possible time. Hot flashes, one of the most common symptoms of menopause, affect an estimated 75 percent of women, most of them in their forties and fifties.\nVincent's group recruited 103 women between the ages of 45 and 59 who reported that they had at least five hot flashes per day and were not using any other treatments for them. Half were randomly assigned to receive a series of 10 standardized acupuncture treatments -- needles were placed at the same spots in the arms, legs and lower belly; the other half received sham treatments in which needles were placed superficially near the same locations but away from so-called pressure points.\nVincent said she and her colleagues were disappointed by the results of the study, which was funded by Mayo and prompted in part by the findings from the Women's Health Initiative (WHI), a federally funded study of more than 36,000 women ages 50 to 79.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Article notes that acupuncture has been used for more than 2,000 years.", "answer": 1}, {"article": "Viagra, known generically as sildenafil, is sold by Pfizer Inc for erectile dysfunction and under the brand name Revatio to treat a heart condition called pulmonary hypertension. It is in a class of drugs called PDE5 inhibitors that work in a variety of ways to increase blood flow.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nThe team, working with funds from the NIH and non-profit groups, tested Viagra in mice that had heart damage similar to that seen in muscular dystrophy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n \nThe story reports the new finding of this study in its next-to-last sentence, while leading with old news. The researchers wrote that to their knowledge \u201cthis is the first report of rapid reversal by a drug treatment of the functional symptoms seen in the established cardiac dysfunction that occurs in mdx mice.\u201d But the story lead is that the drug \u201cmight help treat heart symptoms of muscular dystrophy\u201d\u2026 something that has been reported previously not only in mice, but is already being tested in people. This story does not appear to put this latest study in the proper context of other experiments.\nReference:Revatio for Heart Disease in Duchenne Muscular Dystrophy (REVERSE-DMD)http://clinicaltrials.gov/show/NCT01168908", "answer": 0}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story establish the true novelty of the approach?", "explanation": "A bit of historical information in the story makes it clear that online therapeutic agents have been around\u2014in various stages of development\u2014for more than a decade.", "answer": 1}, {"article": "Elastography measures the compressibility and mechanical properties of a lesion. Cancerous tumors tend to be stiffer than surrounding tissues or cysts, whereas benign lesions are more compressible.\n\"There's a lot of room to improve specificity with ultrasound, and elastography can help us do that,\" Dr. Stamatia V. Destounis, a diagnostic radiologist at Elizabeth Wende Breast Care in Rochester, N.Y., and the study's lead author, said in a news release from the Radiological Society of North America. \"It's an easy way to eliminate needle biopsy for something that's probably benign.\"\n\"The visualized portion of a skin lesion can be just the tip of the iceberg, and most dermatologists operate 'blindly' beyond what they can see on the surface,\" Siegel said. \"High-frequency ultrasound provides almost microscopic resolution and enables us to get size, shape and extent of the lesion prior to biopsy.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately describes the novelty of elastography.", "answer": 1}, {"article": "HER2-positive breast cancer tests positive for a protein known as human epidermal growth factor receptor 2, or HER2, which promotes the tumor cell growth. About one of every five breast cancers involves cancer cells that churn out an excess of HER2 due to a genetic mutation. HER2-positive breast cancers are often more aggressive than other types, according to the American Cancer Society.\nBut until the vaccine is linked to an actual survival benefit or improvement in tumor status, Diamond said, no one can say if it helps the patients in a meaningful way.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story stated that \u201cNumerous vaccines to prevent breast cancer recurrence are currently under study\u201d but didn\u2019t explain how the vaccine in question is different than any of those other approaches.", "answer": 0}, {"article": "Tucatinib is a small molecule inhibitor of the HER2 growth factor receptor. The drug works by targeting the HER2 \"tyrosine kinase\" - a link in the chain of communication that allows HER2 receptors to signal the growth of the cell. The fact that it is a small molecule means the drug is able to pass through the blood-brain barrier to act against brain metastases of the disease. HER2+ breast cancer is more likely to affect younger women and also more likely than other breast cancers to metastasize specifically to the brain.\n\"Usually we expect the results of a phase 1 clinical trial to give us data that we can use to guide the results of future treatments. This is a great case in which, for many of these patients, the results were immediate. There are women who are alive today because of this drug,\" says Virginia Borges, MD, MMSc, director of the Breast Cancer Research Program and Young Women's Breast Cancer Translational Program at the University of Colorado Cancer Center. Borges has been a major driver of the drug's development from its invention at Array Biopharm in Boulder, CO and now through clinical trials of the drug, which is licensed to Cascadian Therapeutics of Seattle, WA.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release suggests that tucatinib is unusual because it is taken in pill form, meaning women do not need to visit infusion centers for treatment. It also suggests that tucatinib is unusual because of its small molecular size, enabling the drug to pass the blood-brain barrier. However, no information is provided about how many, or how few, other cancer drugs can be taken in pill form or whether any other anti-cancer drugs currently in use or in testing also can pass through the blood-brain barrier.", "answer": 1}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nThe results of the study, which was supported by the Netherlands Heart Foundation, the National Institutes of Health, and Unilever, were also published in the New England Journal of Medicine.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0Although the product being tested was indeed novel as the story indicated, the story was reported from the standpoint of possible impact the results of the study might have on dietary recommendations or the use of n-3 fatty acid supplements.", "answer": 1}, {"article": "This can result in damaging side-effects, and doctors are particularly keen to avoid it in cases where it offers little benefit to the patient at potentially great cost.\nSpecialists at The Christie and The University of Manchester have made a breakthrough which could potentially improve detection and treatment of anal cancer, as well as have wider implications for other cancers.\n\"These findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life. It is crucial that we tackle what is becoming an increasingly common form of cancer through research studies like this. These findings could provide learnings for other cancers too.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release is fairly clear that the meta-analysis has uncovered/confirmed that statistical misinformation can result from even the best intentioned efforts to improve diagnostic criteria and staging. It would have helped for the release to connect the dots and demonstrate what those data are and what their impact would have on various patients.", "answer": 1}, {"article": "Angioplasty remains the top treatment for people having a heart attack or hospitalized with worsening symptoms. But most angioplasties are done on a non-emergency basis, to relieve chest pain caused by clogged arteries crimping the heart's blood supply.\nResearchers from Canada and the United States followed more than 2,200 patients who had symptoms of heart disease but were considered stable, reports CBS News medical correspondent Dr. Jon LaPook. Half of these low-risk patients received stents and medication. The other half were given only medication: drugs to lower cholesterol, control blood pressure and prevent clotting.\nIn the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly states that stenting is not a new idea.", "answer": 1}, {"article": "Asians are at high risk of developing diabetes even at a healthy weight. By following the limited guidelines and only screening patients who are overweight or obese, approximately 30 percent of Asians with prediabetes or type 2 diabetes would be identified. That would leave 70 percent of Asians with prediabetes or diabetes undiagnosed until their next screening test, which could occur years later.\n\"This seems like a no-brainer to screen patients who have any of these additional risk factors,\" said lead author Dr. Matthew O'Brien, assistant professor of medicine at Northwestern University Feinberg School of Medicine. \"By demonstrating how well these expanded criteria work in identifying patients with prediabetes and diabetes, we're proposing a better path for the USPSTF to strengthen its screening guidelines.\"\n\"The earlier patients are diagnosed with these conditions, the sooner they can begin to combat them,\" O'Brien said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release states that the study is the first to \u201creport on how these expanded screening criteria would perform in practice among a nationally representative sample of U.S. adults.\u201d It also mentions that the research builds the study author\u2019s previous work. As noted above, the release should have included more hard data from the study to back up its argument. ", "answer": 1}, {"article": "Every medical specialist Jason has seen tried to correct his flat feet, but with little agreement on how to do it.\nThe key measure of success, said Jeffrey P. Wensman, director of clinical and technical services at the Orthotics and Prosthetics Center at the University of Michigan, is that patients feel better.\nBeing generous about studies with design flaws that could overstate effects, Dr. Nigg and his colleagues concluded that custom-made orthotics could help prevent and treat plantar fasciitis, a common injury to a tendon at the bottom of the foot, and stress fractures of the tibia, along the shin. They added, though, that the research was inadequate for them to have confidence in those conclusions.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The shoe inserts described in this study are widely available and are not particularly novel in concept or design. The article did not \u201chype\u201d particular orthotics because of innovative characteristics or qualities.\n\u00a0\n", "answer": 1}, {"article": "While some subjects on all doses experienced mild weight gain and decreases in so-called \"good\" HDL cholesterol, DMAU appeared safe. All participants passed safety tests including liver and kidney health checks.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nThe study was funded by the National Institutes for Health.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A 1980 journal article trumpeted \u201cChina Invents Male Birth Control Pill.\u201d 2003 saw the publication of a book titled \u201cThe Male Pill: A Biography of a Technology in the Making.\u201d As recently as 2016, news releases have talked about research such as \u201cmale birth control shots\u201d that \u201cprevent pregnancy\u201d (we reviewed that one). In short, research into pharmaceutical contraceptives for men has been an active field for decades \u2014 and premature announcements of breakthroughs date back at least 38 years. This story quotes a researcher involved in the recent study as saying the findings are a \u201cmajor step forward\u201d and are \u201cunprecedented in the development of a prototype male pill.\u201d But it doesn\u2019t tell us why. What makes this study, or this pill, different?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article notes that the popularity of knee replacement is expanding from older people to younger ones, suggesting that the operation is not new.", "answer": 1}, {"article": "That wisdom comes from a careful medical assessment and ongoing surveillance of blood pressure, blood work, breast changes, side effects and effectiveness.(Women who\u2019ve had breast cancer cannot take hormone replacements.)\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\nJohnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There is nothing novel about the approaches described in the story.", "answer": 2}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that laminectomy is one of the most common operations performed in the U.S., suggesting that it is not novel. Most readers likely know that nonoperative treatments such as pain medications and physical therapy are not new.", "answer": 1}, {"article": "For example, she might be 4.4 times more likely than women without a particular genetic variant to have a condition known as primary ovarian insufficiency, characterized by irregular periods and diminished fertility before age 40.\nBeim, the Celmatix CEO, said the test is already bringing \u201ctremendous\u201d value, in part by providing guidance that can act as a \u201ctiebreaker\u201d to help patients and their doctor decide which treatment to prioritize.\nCelmatix is mostly marketing the test to reproductive specialists, who are largely using it in the toughest infertility cases, Beim said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Many fertility clinics offer genetic testing. It is possible that Fertilome is unique to the extent that it looks for nearly 50 genetic variants. But the story doesn\u2019t clearly explain how this is different from other genetic tests that may be offered to help couples conceive.", "answer": 0}, {"article": "Tamoxifen blocks the effect of the hormone estrogen, which fuels tumor growth in estrogen receptor-positive cancers that account for about 65 percent of cases in premenopausal women. Some small studies in the 1990s suggested that there was no benefit to using tamoxifen longer than five years, so that has been the standard.\nMr. Peto said he thought the results of the Atlas study would \u201capply to endocrine therapy in general,\u201d meaning that 10 years of an aromatase inhibitor would be better than five years. Other doctors were not so sure.\nThe new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen. They came from about three dozen countries. Half were chosen at random to take the drug another five years, while the others were told to stop.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This criterion was adequately addressed as the new additional information provided by this study was made clear.", "answer": 1}, {"article": "But raloxifene did not prevent two other serious breast conditions, whereas tamoxifen did reduce their risk by 50 percent. Those conditions, sometimes called noninvasive breast cancers, are L.C.I.S. and D.C.I.S., for lobular and ductal carcinomas in situ. Lobular growths increase the likelihood of invasive cancer, and ductal ones can become invasive. D.C.I.S. is often treated like breast cancer, with surgery and radiation.\n\"The outcome of the study is not as clear cut as we might have hoped for,\" said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. \"It will take some time for experts to review the data to determine which of the two treatments is preferable.\"\nWhen it came to L.C.I.S. and D.C.I.S., the difference between the two drugs was statistically significant, meaning it was likely to be real and not due to chance. Yet that distinction was not pointed out in the news release, and, Dr. Lichtenfeld noted, it was \"de-emphasized\" during the news conference.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that raloxifene is an existing drug but that Eli Lilly is asking the FDA to approve it for another purpose.", "answer": 1}, {"article": "Tel.: 45-2143-3302\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB). The findings suggest that for most people with prediabetes, a diet rich with vegetables fruits and wholegrains should be recommended for weight loss and could potentially improve diabetes markers. For people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss. These diets could also be effective independent of caloric restriction.\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN). Presented at the American Diabetes Association's 77th Scientific Sessions on June 11, 2017, the additional research includes an examination of patients in the Prevencion Dieta Mediterranea (PREDIMED Study), a Randomized Trial of a Low-CHO Diet for Obesity (CHO Study), and The Healthy Weight for Living Study. The different studies (six in total) employed a variety of nutrition strategies, including caloric restriction and ad libitum diets, varying the contributions of carbohydrate and fat, and increasing fiber intake.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The idea that vegetables, fruits, whole grains, and healthy fats should be recommended for weight loss is hardly new. And yet the release frames these results as \u201cpotentially [leading] to a breakthrough in personalized nutrition.\u201d We\u2019d need more proof of tangible benefits before agreeing with that characterization.\u00a0", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly notes that these techniques were originally developed for use in brain surgeries, but are now being considered for use in a variety of other procedures \u2014 and have been since at least 2011.", "answer": 1}, {"article": "Standard therapies include over-the-counter pain meds, corticosteroid spinal injections, and/or invasive spine surgery that sometimes involves disk removal and vertebrae fusion.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"The rationale for using pRF on disk herniation is that we eliminate the inflammation process of the compromised nerve root,\" he explained. \"Without inflammation the pain fades, and the body starts a self-healing process that allows for complete resolution of the disk herniation in a large proportion of patients.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explains early on that pRT is \u201cnot new\u201d although it\u2019s claimed that recent technology advances enable doctors to deploy it with better accuracy.", "answer": 1}, {"article": "According to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The broadcast did lay out for viewers that currently, it is only after death that Alzehimer\u2019s disease can be definitely diagnosed and so if this test were demonstrated to be valid, it would represent something new.", "answer": 1}, {"article": "When a person suffers a heart attack, he or she is often left with huge areas of scarring in the heart. Scarred heart muscle doesn't pump blood as well as it used to, putting stress on other parts of the heart to make up for the deficit. The damaged area also doesn't conduct electric current as well, leading to an abnormal heart rhythm, which can cause more problems. Heart attack patients often go on to develop heart failure.\nTo qualify for this clinical trial, patients had to have suffered a recent heart attack and \"had to have a significant amount of damage to begin with and weren't squeezing [blood into the body] as well as they should have,\" says Dr. Peter Johnston, one of the study authors who injected the new heart cells into patients treated at Johns Hopkins Hospital.\nMarb\u00e1n says when the first patient data came in, he and his colleagues were relieved to see the procedure was safe. After 12 months, researchers report only one patient appeared to have a serious side effect that may have been connected to the experimental cells.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story improves on a competing WebMD story by explaining the novelty of this study. \u201cThis is the first instance of therapeutic regeneration,\u201d says Dr. Eduardo Marb\u00e1n, director of the Cedars-Sinai Heart Institute. He says while nature abounds with examples of spontaneous regeneration of limbs or tissues \u2013 like a salamander\u2019s new tail or a human liver regrowing to full size if partially damaged \u2013 doctors have not been able to help patients regrow heart tissue. This could change in the future if larger clinical trials and longer patient outcomes confirm the results of this early research published Monday in the journal The Lancet.\u00a0 Marb\u00e1n and his colleagues first presented this research at an American Heart Association conference in November.\n\u00a0", "answer": 1}, {"article": "In one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nResearchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThis story summarizes the results of the study without inflating the novelty of the approach. However, it would have been helpful to provide some background pointing out that there have been other studies that also explored the use of spinal fluid tests to aid Alzheimer\u2019s diagnosis and that proposed guidelines already include using spinal fluid tests to help clinicians identify the likely cause of memory problems in patients.", "answer": 0}, {"article": "Sufferers can also opt for localized surgery, like liposuction, to remove or injure sweat glands. Oral medicines can be used to systemically limit sweating. For instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\nBased on the most recent estimates, about 7.8 million Americans have some form of excessive sweating including palms, feet, underarms or head, and about half of this population suffer from the underarm form, said Dermira spokeswoman Erica Jefferson, in an interview ahead of the data readout.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes no unfounded claims about novelty, and the story makes it clear that an effective topical treatment via wipes would be new for this condition.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story establish the true novelty of the approach?", "explanation": "This ties in to what we said above regarding alternatives. By explaining several surgical interventions that address uterine fibroids, the story clearly articulates what is novel about the Sonata approach. Well done.", "answer": 1}, {"article": "The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No. 15 nationally in the 2016-2017 \"Best Hospitals\" issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation's top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke's, and Mount Sinai West are ranked regionally. Mount Sinai's Kravis Children's Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in \"Best Children's Hospitals.\"\n\"The cochleostomy approach causes fibrosis and scarring, leading to hearing loss over time,\" said Dr. Wanna. \"Our results also revealed that using oral steroids also helped in the long term to preserve hearing by preventing inflammation.\"\n\"We hope the findings will help surgeons choose the best implants and approaches for their patients,\" said Dr. Wanna. \"This is an exciting time in this field, and the advancement in hearing technology and continued improvements in techniques and outcomes will benefit patients and their families.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release doesn\u2019t tell us anything about the novelty of the wireless cochlear implants nor that of the \u201cround window\u201d (where surgeons open the membrane without bone removal or drilling in the inner ear) and \u201ccochleostomy\u201d (which requires drilling into the bone to get inside the inner ear). \u00a0Are these new procedures? \u00a0What other research has been done on them? \u00a0Where is the context that establishes the place of these in the current landscape of hearing-preservation technologies?", "answer": 0}, {"article": "There is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase. HER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches.\nIn addition to bringing to the table a novel treatment for metastatic breast cancer carrying a HER2 mutation, the researchers have tested the value of the circulating tumor DNA as a disease-monitoring marker.\n\"This is the first time we had a reasonable number of patients treated for HER2 mutations in whom we could estimate the response rate.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release made it seem that neratinib was an experimental drug that could be used for women with a particular gene mutation related to HER2+ metastatic breast cancer. It wasn\u2019t made clear that neratinib is already used to treat early-stage HER2+ breast cancer.", "answer": 0}, {"article": "The European League Against Rheumatism (EULAR) is an umbrella organisation which represents scientific societies, health professional associations and organisations for people with rheumatic diseases throughout Europe.\nThe OPTTIRA study is a 12-month multicentre, randomised controlled trial designed to evaluate if reducing TNFi doses (of either etanercept or adalimumab) caused a loss of response in RA patients who were also receiving a synthetic DMARD. To be eligible, patients had to demonstrate stable low disease activity (DAS28 less than 3.2) for over three months. Patients with serious concomitant illness, or those taking high-dose steroids (more than 10mg prednisolone daily) were excluded.\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t establish novelty. The implication is that the approach is new, but is this the very first time that such a strategy has been tested? If so, where did the idea come from? If not, what did previous studies of this approach find? A bit of background would have been useful.", "answer": 0}, {"article": "Obsessive behaviors may also arise in autistic people in response to the stress or discomfort of unpredictable situations. \u201cMany of these individuals have expectations for what\u2019s going to happen, and if there is an unexpected deviation, they experience a lot of discomfort and then they do all these kinds of behaviors,\u201d says Hollander. That\u2019s why people with autism may obsessively avoid locations where they previously experienced discomfort, for example, or they may engage in a repetitive habit like washing, checking, counting, touching or tapping.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful. \u201cThe clinicians could tell that people were doing better not only in terms of OCD symptoms but overall distress and ability to function.\u201d\nWhen taking Prozac, Hollander says, \u201cPatients acknowledge experiencing less discomfort. They\u2019re more able to go outside their comfort zone and to better resist their habits and rituals.\u201d One participant in Hollander\u2019s study was previously too anxious to take the subway or eat in a restaurant, but, when taking Prozac, was able to tolerate these unpredictable environments.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The novelty of the finding is at least implied.\u00a0 This small study increases the number of patients studied in randomized clinical trials by about 15% and it is in adults.\u00a0 With the exception of the earlier RCT published in Archives Gen Psy (N=149) \u2013 in children \u2013 there are just a handful of small studies on this topic.\n\u00a0", "answer": 1}, {"article": "Lung cancer is the leading cause of cancer death. The American Cancer Society (ACS) estimates that more than 224,000 Americans will be diagnosed with lung cancer this year, and more than 158,000 lung cancer patients will die\u2014that translates to 433 lung cancer deaths per day in the United States.\n\u201cThe rapid normalization of almost all of the four compounds after surgery provides strong evidence that they are directly produced by the tumor environment,\u201d said Dr. Schumer. \u201cThis study confirms that the technology is accurate.\u201d\n\u201cThe great potential with breath analysis is detecting lung cancer at any point, both as a primary screening tool and to follow patients after disease has been treated,\u201d said Dr. van Berkel. \u201cThe technology is pretty robust. Our next step is getting approval from the FDA.\u201d\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t make a strong claim of novelty \u2014 and that\u2019s appropriate.\nA quick online search found that besides this research from the University of Louisville in Kentucky, at least two other institutions are developing breath tests for lung cancer detection: Georgia Institute of Technology and the Winship Cancer Institute of Emory University\u00a0 and the University of Leicester.\nThe release said \u201cA subset of four VOCs\u2014called carbonyl compounds because of their carbon base\u2014have been discovered in the exhaled breath of lung cancer patients.\u201d Discoveries sound novel. But this study, more than a decade old, describes the use of VOCs for lung cancer detection. \nWhile the release doesn\u2019t claim to be \u201cfirst,\u201d it might have mentioned related work that has been done in this field of research.", "answer": 0}, {"article": "Rheumatoid arthritis, which is felt throughout the whole body, is caused when a person's immune system attacks his or her own tissues. Osteoarthritis, which is usually felt only in the joints, is caused by wear and tear on the body.\nFor the study, the investigators analyzed the findings of 40 studies published between January 1990 and December 2011. The studies included arthritis patients aged 18 or older who had hip or knee replacements.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty was not at issue.", "answer": 2}, {"article": "Montmorency tart cherries are the most common variety of tart cherries grown in the U.S., and are available year-round in dried, frozen, canned, and juice forms - including juice concentrate, which was the form used in this human trial. Montmorency tart cherry juice concentrate can be mixed with water or other juices. It can also be consumed straight from the bottle or used as an ingredient in recipes, such as smoothies and other beverages.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nThis study was made available online in April 2018 ahead of peer-review and publication this month.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release mentions the study is \u201ca first-of-its-kind trial\u201d of humans combined with a parallel laboratory study.\nIt\u2019s mentioned in the published study that, to the authors\u2019 knowledge, this is the \u201cfirst microbiota/metabolome investigation of the impact and fate of tart cherries and their polyphenols in the human colon.\u201d", "answer": 1}, {"article": "Fetal death, or intrauterine fetal demise (IUFD), affects 30,000 women each year in the United States. About 25% of all women who become pregnant have a first-trimester loss. But for some women, every pregnancy results in a loss. The researchers studied the effects of micronized plant-derived progesterone in 116 of these women who had experienced two or more pregnancy losses.\nThe researchers believe that the progesterone caused the patients' endometrium to produce more endometrial secretions. \"The endometrium feeds the baby up until the eighth week of pregnancy. Then at 9 to 10 weeks the mother's blood takes over to feed the embryo,\" said Kliman.\nOther authors on the study included Dana McQueen, M.D., and Michelle Wintes, M.D.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This release doesn\u2019t establish the novelty of this approach. Other research studies have looked at the use of progesterone in preventing miscarriages.\nAccording to the reference site \u201cUpToDate\u201d by medical publishers Wolter Kluwer, more than 50 research studies have examined the use of progesterone in preventing miscarriage or pre-term birth, with mixed results.", "answer": 0}, {"article": "In 2006, the first inhaled insulin, Exubera, received FDA approval. However, the drug was pulled from the market in October 2007 by its manufacturer, Pfizer, because of disappointing sales. From the beginning, concerns surfaced about the effects the drug might have on the lungs. One study found a reduction in lung function for some, but of more concern was an increased risk of lung cancer associated with its use. This finding came after Exubera had been pulled from the market, and the sample size wasn't large enough to draw a definitive link between the drug and the increased risk of lung cancer.\n\"They have done the required safety studies and come out clean, but it's only been tested for six months, so long-term isn't known,\" said Sanjoy Dutta, director of the insulin initiative at the Juvenile Diabetes Research Foundation.\nDutta confirmed that Afrezza is fast-acting and less likely to cause low blood sugar. \"Just as quickly as it has an onset of action, it also has a quick off mechanism. It doesn't stay around long enough to cause hypoglycemia,\" he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article doesn\u2019t explain how the inhaler technology differs from that used in Exubera, only that Afrezza is a dry powder dissolved in the lungs, absorbed into the bloodstream. \nAlso, from what we can see, the overall therapeutic role of Afrezza is no different than that of Exubera. People who need to take insulin to treat their diabetes would need injections of long-acting (basal) insulin and then puffs of mealtime (prandial) insulin. From what we are told in this story, the true novelty of Afrezza over Exubera would be a) its shorter mechanism of action and b) the fact that Exubera has ceased to be. They haven\u2019t demonstrated that Afrezza has a different safety profile in humans from that of Exubera. (Other sources we found quote Dr. Leone-Bay noting that the Afrezza inhaler has unique properties.) The claim of superior glucose control over injectable insulin is unsubstantiated in the story, yet it\u2019s critical information.", "answer": 0}, {"article": "In the meantime, Neylan offers insomniacs some advice: \u201cIf you\u2019re not ready to fall asleep, don\u2019t lie down in bed and try to force yourself to sleep. And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\nBuysse and his colleagues wondered if the pill-free treatment could be shortened and simplified, providing more rapid results at a lower cost.\nWhile brief behavioral treatment for insomnia is not yet generally available, Monk told Reuters Health in an e-mail that his team hopes their findings will be \u201can important first step in that process.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThis story suggests that there are no brief behavioral interventions available to people with insomnia. They story should not have suggested that the only alternative treatments are drugs and expensive cognitive behavioral therapy. ", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article makes clear that the drug is on the market and used for related conditions, but its use in relapsing-remitting MS patients is being explored in this research.", "answer": 1}, {"article": "Feb. 22, 2010 -- Acupuncture may be an effective way to reduce depression during pregnancy, a new study shows.\n\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\nThe study included 150 pregnant women diagnosed with major depressive disorder. Some received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While prior research\u00a0has studied the effects of acupuncture on depression, it\u2019s still a novel treatment approach. Unfortunately, we can\u2019t tell this from the story. \n\u00a0\n\u00a0", "answer": 0}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that researchers are exploring a new use of an existing product.\u00a0 ", "answer": 1}, {"article": "\u2022 1.5 ounces of 80-proof spirits or 1 ounce of 100-proof spirits.\n\"There may be some evidence that perhaps one glass with a meal is OK,\" says Demetrius Lopes, a neurological surgeon at Rush University Medical Center, Chicago, and another spokesperson the heart association. \"But it's a slippery slope to saying 'OK, maybe two is better.' I do think people don't know the dangers.\"\nStudies will continue, and not everyone has given up the idea that moderate drinking \u2014 up to two drinks a day for men and one day for women \u2014 might have some cardiovascular benefits.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The report briefly went into how a couple of recent studies may be challenging the claim that alcohol is good for your heart. But it didn\u2019t give much background on why these studies differ from dozens of previous studies that have reported potential benefits of moderate alcohol consumption. Researchers argue that participants were poorly selected or grouped in the past. A bit more discussion on this issue in the story would have been welcome.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story clearly indicates that this is the first large-scale study to evaluate the role of statins in increasing survival associated with the flu. The story also mentions previous research, which found that statins can improve survival from other infectious diseases.", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that CAD is a newer method of reading mammographies, but in a recent observational trial it was no better\u2013and may have produced more false positives\u2013than images read and interpreted by radiologists alone.", "answer": 1}, {"article": "HONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Some research has been published about electroacupuncture for mental illness \u2013 including by this same research group \u2013 yet the story didn\u2019t hint at any of it.", "answer": 0}, {"article": "Philadelphia, PA, August 14, 2017 - Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood. The test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction. According to the report in The Journal of Molecular Diagnostics, this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer.\nAfter generation of customized mutation detection assays, the researchers were able to identify tumor-derived circulating DNA from three out of six patients. In one patient, the assay was able to show the presence of three different mutations. The three patients, whose samples did not show elevated cancer DNA, were undergoing active treatment at the time of collection.\nThe report describes the use of the test to analyze samples from six patients. Five patients were previously diagnosed with colorectal cancer and one with cholangiocarcinoma.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release establishes novelty here:\nThe test, which is called single color digital PCR, requires only a fraction of a tube of blood and can detect as few as three mutation-bearing molecules in a single reaction.", "answer": 1}, {"article": "First published on June 22, 2006 at 12:00 am\nWhile he called his study's findings encouraging, Dr. Merriam declined to characterize them as a breakthrough, saying more work is needed to determine both the safety and the benefits of the treatment.\nOther researchers involved in the study were affiliated with Duke University, Stanford University, the University of Arkansas, Johns Hopkins University, the Veterans Affairs health care system, and Pfizer, which supported the project.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Promoting growth hormone to counteract the effects of aging, namely physical functioning, is not new. However, the benefit of this has not been established and safety of growth hormone for this use in older adults in unknown. The story does note that this study does not represent a breakthrough in preventing age-related decline in physical or cognitive functioning. ", "answer": 1}, {"article": "Nasal pain, discomfort or burning (10.3%); transient electrical discomfort (5.2%); nosebleed (5.2%); nasal congestion (3.1%); headaches (2.1%); trace blood, dot heme in nostril (2.1%); facial pain (2.1%); sore eye (1.0%); sinus pain (1.0%); periorbital pain (1.0%); runny nose (1.0%); nasal ulcers (1.0%); and light-headedness (1.0%).\nTrueTear\u2122 provides a temporary increase in tear production during neurostimulation in adult patients.\nAllergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release says this is the first neurostimulator intended to increase tear production in patients with dry eye problems.", "answer": 1}, {"article": "Jan. 11, 2011 -- The herpes zoster vaccine, better known as the shingles vaccine and recommended for adults 60 and older, cuts the risk of getting the painful disease by 55%, new research finds.\nThe new study is published in the Journal of the American Medical Association.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\n\nThe story makes clear that this is the only vaccine approved to reduce the risk of shingles and that it has been available in the United States since 2006. However, it fails to explain what is new about the information provided by this study. The other stories we reviewed (HealthDay and Reuters) explained that this study offers a glimpse at how the vaccine is performing in the real world, as opposed to the idealized conditions of the clinical trial that led to the vaccine\u2019s approval.", "answer": 0}, {"article": "The use of complementary and alternative medicine for the management of menopause symptoms has surged in recent years as women have attempted to identify alternatives to hormone therapy (HT). Although HT is the most effective treatment for managing most menopause symptoms, some women have turned to herbal medicine because they are either not candidates for HT or are concerned about the negative publicity surrounding potential side effects. Fennel, an herb containing essential oils, has phytoestrogenic properties. Phytoestrogens are estrogen-like chemicals in plants that have been used to effectively treat a wide array of menopause symptoms.\n\"This small pilot study found that, on the basis of a menopause-rating scale, twice-daily consumption of fennel as a phytoestrogen improved menopause symptoms compared with an unusual minimal effect of placebo,\" says Dr. JoAnn Pinkerton, executive director of NAMS. \"A larger, longer, randomized study is still needed to help determine its long-term benefits and side effect profile.\"\nIn this small trial of 79 Iranian women aged 45 to 60 years, soft capsules containing 100 mg of fennel were administered twice daily for eight weeks. Improvements were compared between the intervention and placebo groups at four, eight, and 10 weeks, with a significant statistical difference documented. In the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects. The study described in the article \"Effect of Foeniculum vulgare Mill. (fennel) on menopausal symptoms in postmenopausal women: a randomized, triple-blind, placebo-controlled trial\" is one of the first clinical studies to examine the benefits of fennel for managing menopause symptoms, even though it had been previously studied and confirmed to manage premenopause symptoms.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news hook here is that results of this\u00a0study are billed as \u201cconfirmation\u201d of benefits \u2014 an overstatement \u2014 but also that the study is one of the first undertaken with scientific rigor. It\u2019s hard to say if that is so, but the release makes a reasonable case, albeit based on a very brief trial.", "answer": 1}, {"article": "\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\u2022 select an item from our site index below\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Described within this story as \u2018a new device\u2019 and that \u2018about 100 hospitals around the country already are using the treatment\u2019 which suggest that this is a relatively new approach.", "answer": 1}, {"article": "Federal regulators also will have to weigh potential interactions of cannabidiol with other anti-seizure drugs. Another study scheduled for presentation at the meeting found that CBD appeared to enhance the effects of the epilepsy medication levetiracetam (Keppra), when given to lab mice.\n\"We know that our placebo rates can be as high as 30 percent, and sometimes higher,\" said Dr. Amy Brooks-Kayal, American Epilepsy Society president, who wasn't involved in the studies.\nIf CBD proves effective in controlled trials, it could be two to five years before the drug is approved by the U.S. Food and Drug Administration, Devinsky noted.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Since cannabis has been used for the treatment of seizures for centuries, it\u2019s curious why the researchers didn\u2019t test the compound in a better designed trial (randomized, blinded and placebo controlled). The public and patients are still left with the question of whether this works. But the story does briefly mention previous studies that have looked at cannibidiol in adults, so the story gets a pass here.", "answer": 1}, {"article": "But two days later, most patients were satisfied. Overall, nearly 83 percent of acupuncture-only patients said they would probably or definitely repeat their treatment, compared with about 81 percent in the combined group, and 78 percent who took painkillers alone.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen. He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It would be pretty novel if the study had shown that acupuncture was more effective than conventional analgesic drugs in controlling pain, but that\u2019s not what this study showed. While\u00a0both the study and the story\u00a0did seem to indicate that acupuncture was as effective as either painkillers or painkillers and acupuncture, the\u00a0abstract of the study\u00a0also said \u201cnone of the examined therapies provided optimal acute analgesia.\u201d Controlling pain was arguably the reason the study\u2019s patients went to the emergency departments. The study basically said acupuncture was as good as painkillers for pain control but that for these patients, neither was successful. We think that should have been explained in the story to help establish the novelty of this research.", "answer": 0}, {"article": "However, they were 3.8 times more likely to experience a serious adverse event, such as an infection, falls, nervous system or psychiatric disorders, or a problem with the device. Forty-nine of the deep brain stimulation patients, or 40%, had 82 serious adverse events, compared with 11% of the drug patients, who had 19 serious adverse events.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\nThe problem with deep brain stimulation is that many doctors are not aware of its benefits or don't know how to determine the appropriate patients based on risks vs. potential benefits, he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "While the lede implies the surgery is exotic, later in the story the report makes clear that it is done with some regularity and is being studied for use on other conditions. \nThe reporter includes specifics: About 15 percent of Parkinson\u2019s patients may qualify for the surgery, yet only 2 percent of patients get it. \nIdeally this information would have been placed higher in the story so Parkinson\u2019s patients and caretakers understand the limited applicability.\u00a0 ", "answer": 1}, {"article": "In addition, each micromolar increase in blood homocysteine level raised the risk of Alzheimer's disease by 16%.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease. Researchers found that each picomolar increase in blood vitamin B12 level was associated with a 2% reduction in the risk of Alzheimer's disease among the elderly.\n\"The few studies that have investigated the usefulness of vitamin B12 supplements to reduce the risk of memory loss have had mixed results,\u201d says Hooshmand.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "", "answer": 1}, {"article": "They found that the saliva of people with Alzheimer's had different levels of certain substances compared to the saliva of healthy people or those with mild cognitive impairment.\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\n\"There are many gaps in the evidence,\" Reiss said. \"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The research discussed here is novel in a general sense, but the story doesn\u2019t establish this to a satisfactory degree. A number of previous studies have looked at saliva markers of Alzheimer\u2019s, and there are probably dozens of other blood tests, scans, and other approaches currently in development to address the diagnosis of Alzheimer\u2019s disease. The story does not allude to this research", "answer": 0}, {"article": "The reasoning has been that a diet rich in omega-6 polyunsaturated fats lowers cholesterol, and is therefore good for heart health. But an updated look at the study indicates that heart disease patients who follow this advice may actually increase their risk for death.\nThe 458 male participants in the original study had been between the ages of 30 and 59 at enrollment, and all had a history of heart disease, with most having survived a heart attack.\nBy newly crunching all the original data the NIH team found that, compared to the no-dietary-change group, the linoleic acid group faced a higher risk of death, from both heart disease specifically as well as from all causes overall.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It has long been known that the\u00a0subjects in the linoleic acid/safflower oil group of this study had higher all-cause mortality. What was unclear is if they had higher cardiovascular mortality.\u00a0The results are not quite as novel as the story suggests.\u00a0 Nonethless, we\u2019ll give the story the benefit of the doubt on capturing the overall gist of the novelty of the study adequately.", "answer": 1}, {"article": "Alpha-carotene is part of a group of antioxidants known as carotenoids, which also includes beta-carotene and lycopene. Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\n\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThere is no claim of novelty in this story. However, the story fails to make clear how this study was different from other research on this topic.", "answer": 2}, {"article": "Provenge from Dendreon, by contrast, trains the patient\u2019s immune system to attack the tumor. The drug was approved by the Food and Drug Administration in April after a clinical trial showed that those getting the drug had a median survival of about 26 months, four months longer than those in a control group.\nDrugs now used to treat advanced prostate cancer, like Taxotere, do not have much affect on bone scans, Dr. Smith said. Bone drugs like Zometa from Novartis and denosumab from Amgen can protect cancerous bones from fractures, but have not been shown to fight the cancer itself.\nAnother investigator in the trial, Dr. David C. Smith of the University of Michigan, said he could not believe it when the bone scan of one patient, who previously had widespread cancer in his bones, came back completely clean.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was clear about the novelty of the two drugs presented.", "answer": 1}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death. Even though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\n\"Using an approved flu vaccine in a novel dosing schedule yielded promising results for a group patients at high risk for infection,\" Branagan said. \"We hope to confirm these results in a larger prospective randomized trial that is underway now at Yale during the 2015-2016 flu season. We suspect this strategy could benefit other cancer patient populations.\"\nThis study was supported by the Arthur R. Sekerak Cancer Research Fund a Yale Cancer Center philanthropic fund.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release notes that using a follow-on booster of the high-dose vaccine is a novel flu prevention strategy in patients with cancers that affect the immune system. This approach of adding a booster is used in immune-suppressed patients with\u00a0other vaccines as well.", "answer": 1}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\nUsing a high sensitivity blood test [1], researchers have identified the optimal level of a protein called troponin that could rule out a diagnosis of heart attack for two-thirds of people attending the emergency department, according to new research published in The Lancet. Using this threshold in routine practice could potentially double the number of patients suitable for immediate discharge directly from the emergency department, say the authors.\nAccording to Dr Shah, \"Over the last two decades the number of hospital admissions due to chest pain has tripled. The overwhelming majority of these patients do not have a heart attack. This study shows that low plasma cardiac troponin concentrations at presentation identify up to two-thirds of patients who are at very low risk of heart attack and could be safely discharged from the Emergency Department. Use of this approach is likely to have major benefits for both patients and healthcare providers.\"[2]\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news hook for this release is pretty well established.", "answer": 1}, {"article": "Aromatase inhibitors cause side effects in some women, especially night sweats, hot flashes, and sexual dysfunction. Women receiving five more years of letrozole also had greater loss of bone in their hip, worse osteoporosis, and more fractures.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial. If you can tolerate the side effects, I think many women will opt to take the extra years of letrozole, so this study is practice-changing.\u201d\n\u201cThe reason this is a milestone trial is that it\u2019s the first to show that 10 years [on letrozole] is better than five,\u201d said Dr. Nicholas Robert, an oncologist with Virginia Cancer Specialists and a co-author of the study. But because the absolute benefits were not huge, and because the drug did cause side effects, it makes sense to consider this for women at the highest risk of a recurrence of breast cancer, he said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story adequately establishes the novelty of the study:\n\u201cThe reason this is a milestone trial is that it\u2019s the first to show that 10 years [on letrozole] is better than five,\u201d said Dr. Nicholas Robert, an oncologist with Virginia Cancer Specialists and a co-author of the study.\n\u201c\u2026If you can tolerate the side effects, I think many women will opt to take the extra years of letrozole, so this study is practice-changing.\u201d\nThis is important because many patients already continue aromatase inhibitors:\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years. There had been no research on whether that was beneficial.", "answer": 1}, {"article": "For more about premature birth, visit the U.S. National Library of Medicine.\nThe test may cost $150 to $250, Graves said. It would require several years to go through the U.S. Food and Drug Administration approval process. BYU and the University of Utah have a patent on the test and have licensed it.\nIn the new study, the researchers examined blood samples from 80 women who went on to have normal births and 80 who had premature births. They tried to find signs in the blood that indicate what kind of birth the women would have.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story never put the new test into the context of other research attempts to study what to do to predict prematurity. So its real novelty \u2013 and role \u2013 isn\u2019t clearly established.", "answer": 0}, {"article": "Gluten is a protein found in wheat, barley, and rye. People with celiac disease experience an immune reaction when they eat gluten that can lead to intestinal damage and impact the health of other organs if it's not managed well. It can cause stomach pain, a swollen belly, acid reflux, diarrhea, skin problems, and other symptoms.\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This is not the only product under the sun designed to quick-test for gluten, although to be fair, it\u2019s unclear whether another product would be better/worse/as good. A quick online search identified\u00a0a number of consumer kits available. It is unclear why a story focusing specifically on this particular device is news.", "answer": 0}, {"article": "Essential fatty acids are substances that are not produced by the human body and are only available from diet. Eggs, nuts, vegetable oils and fish are examples of foods that provide such acids, which are also available in supplement form.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nAccording to the study, the 120 women who participated reported few side effects, and most of those were mild and may have been due to sensitivity to mineral oil, the placebo taken by some of the participants.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The idea of using supplements for PMS is not new, and the authors mention past research on the same topic.", "answer": 1}, {"article": "Wolters Kluwer reported 2014 annual revenues of \u20ac3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups. The implant procedure is minimally invasive, has few complications, and produces significant and lasting improvements in pain, disability, and quality of life.\nThe authors note some important limitations of the trial, including the lack of long-term outcomes in the nonsurgical group due to the high crossover rate. They plan further analyses, including two-year follow-up CT scans and a cost-effectiveness comparison of SIJ fusion versus nonsurgical treatment.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release identifies the study as the first randomized trial of a surgical procedure versus conservative,non-surgical care for SIJ dysfunction.", "answer": 1}, {"article": "By contrast, surgical cancer removal often means several hours in the operating room, complications of general anesthesia and weeks or months of recovery. Surgery also typically involves significant breast tissue damage and disfigurement due to large incisions and removal of sizable breast mass.\nPhysicians participating in the trial report that patients feel minimal discomfort and can watch the procedure on the ultrasound screen. Most are extremely relieved to avoid painful, disfiguring surgery and long recovery times.\n\"For women with certain types of breast cancer, cryoablation is showing promise as an alternative to surgery, particularly for patients over age 65,\" says Susan K. Boolbol, MD, Chief of the Appel-Venet Comprehensive Breast Service, Mount Sinai Beth Israel, who is participating in the trial. \"For older patients the risks associated with invasive procedures and general anesthesia as well as the discomfort of long recoveries also makes this procedure particularly desirable. As our understanding of tumor biology grows, the ability to offer treatment options other than surgery is important.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Breast cancer isn\u2019t normally treated with cryoablation, and the release makes this clear. We\u2019re also told the improvements built into ICE3 makes treating cancer with it \u201cmore precise\u201d and reliable.", "answer": 1}, {"article": "As laws that permit medical cannabis have expanded nationwide (29 states in the country now permit some form of cannabis use for medical purposes), cancer patients increasingly use the drug to alleviate the harsh symptoms of chemotherapy, such as nausea, anxiety, loss of appetite and insomnia. But there\u2019s also an emerging body of research that suggests marijuana might be effective as a treatment for cancer on its own, or in conjunction with standard therapies.\nRELATED: What we know about how cancer starts could all be wrong\nThe findings so far from published lab studies suggest cannabidiol (CBD), one of more than 100 cannabinoids present in the plant, targets certain pathways in leukemia. The evidence indicates that leukemia cells have a high number of cannabinoid receptors\u2014primarily the receptor CB2. The proteins on the cell membrane (receptors) recognize the chemical compound, CBD. The shape of the receptor mirrors the shape of the compound, enabling the CBD to land and attach to the cell. \u201cIt\u2019s like a key in the lock,\u201d says Dr. Bonni Goldstein, medical director of Canna-Centers in Los Angeles and the medical adviser to Weedmaps.com, a resource for people seeking specialists to oversee their medical cannabis treatment. \u201cWhen compounds such as cannabidiol bond to receptors, it causes the cell to die.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story is clear that people have been using marijuana, including cannabis oil, to treat symptoms and side effects of cancer treatment for some time now. It notes that hypotheses about a direct effect on cancer are relatively new\u2026 and remain to be tested in people.", "answer": 1}, {"article": "Chronic neck pain is a leading cause of disability. Usual care for neck pain generally consists of prescribed medications and visits to physical therapists and other health care professionals. In addition, persons with chronic neck pain often seek complimentary care to manage their condition, such as acupuncture or the Alexander Technique. Acupuncture is a procedure in which patients have thin needles inserted into specific points on the body to relieve pain and the Alexander Technique is an educational process that teaches people how to avoid unnecessary muscular and mental tension in everyday activities.\nIn a randomized, controlled trial, both acupuncture and the Alexander Technique led to long-term significant reductions in neck pain and associated disability compared with usual care alone. The study is published in Annals of Internal Medicine.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone. Both interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes. Over time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "What\u2019s novel about this study is the longer term relief gained from the therapies. The study points this out, but the release doesn\u2019t explicitly mention it.", "answer": 0}, {"article": "Which is a problem when it comes to education. Most high schools start before 8 am to help parents get to work by 9 am. Early school start times also give kids more time for after-school activities like sports or theater.\nIn a tightly controlled lab study, 24 healthy adult participants* who had their sleep shifted by one hour each day (simulating jet lag) started to look prediabetic after a three-week trial. Their resting metabolic rates dropped 8 percent. \"Assuming no changes in activity or food intake,\" that \"would translate into ~12.5 pounds increase in weight over a single year,\" the study, published in Science Translational Medicine in 2012, concluded.\nA new meta-analysis in the Journal of Clinical Sleep Medicine analyzed 18 studies on start times. It finds that when school starts up to an hour later, students typically do get around 19 minutes more sleep, on average. When start times are delayed more than an hour, that average increases to 53 minutes of extra sleep.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The reader will learn that the effects of eight or nine hours of sleep a night on teenagers have been demonstrated in other studies. What is novel is the meta-analysis\u2019 reflections on the big picture, which suggests caution in\u00a0making school policy changes on the basis of extant studies.", "answer": 1}, {"article": "As levels of growth hormone-releasing hormone (GHRH) decrease with age, so too do other hormones stimulated by GHRH, such as growth hormone and insulin-like growth factor 1. All of these hormones are believed to play a role in brain health, and decreasing levels of these hormones are suspected to play a role in the development of Alzheimer's disease.\nIn a previous study, Baker and her colleagues demonstrated that treatment with GHRH provided a short-term boost in memory and concentration for healthy adults. In the current study, they wanted to see if GHRH could help restore some function in people who were showing signs of a condition known as mild cognitive impairment. People with this condition don't yet have Alzheimer's disease, but they do have problems with memory and focus, and they're at higher risk of developing Alzheimer's disease, according to the Alzheimer's Foundation.\n\"Growth hormone-releasing hormone doesn't target one specific area in the body and brain,\" said study lead author Laura Baker, an associate professor of psychiatry and behavioral science at the University of Washington School of Medicine, in Seattle. \"It stimulates a whole cascade of hormones in the body and brain; it stimulates normal function of a system that was working at a younger age so that cells can do what they were programmed to do at birth.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least established that the same team had done prior work with GHRH.", "answer": 1}, {"article": "Boston Scientific gets data from patients\u2019 defibrillators. It also gets information on deaths from Medicare.\nDr. Richard Page, president of the Heart Rhythm Society, said doctors wonder if they can be held liable if they do not look at all the data. Still, he said, the new technology \u201cis potentially transformative.\u201d\nDr. Stevenson likened such information to the game of \u201cJeopardy!\u201d \u2014 doctors are given answers in search of a question. It\u2019s a challenge even for the nation\u2019s 1,000 heart failure specialists. But it can be even harder for primary care doctors, who have less expertise in heart failure yet care for most of the six million patients in the country with the condition.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story wove together information from devices that available \u2013 through those used in clinical trials and those under development.", "answer": 1}, {"article": "\"We're not training them on one skill, like doing crossword puzzles,\" she says. \"We're embedding complexity and novelty into their daily lives, something that tends to disappear once people retire. The same things that benefit us at 5, 10, 25, 35 - contact with others, meaningful work - are certain to benefit us as we age.\"\nCarlson notes that many cognitive intervention studies last one year or less. One strength of this study, she says, is that the participants were followed for two years, which in this case was long enough to see changes that wouldn't have been detected after just one year.\nThe researchers were particularly interested in the results, considering that people with less education and who live in poverty are at greater risk for cognitive decline.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The study concept \u2014 a randomized controlled trial of a civic engagement program \u2014 is novel and builds upon findings from a smaller pilot study. However, the release doesn\u2019t establish what is new or different about the study compared with previous research.", "answer": 0}, {"article": "More than 670,000 men are diagnosed with prostate cancer globally every year, making it the second-most common cancer in men, after lung cancer. In the U.S., about 600,000 men are being treated with endocrine therapies for prostate cancer.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\nA common treatment for prostate cancer may slightly increase patients' risk of heart problems, new research says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story does not explain how this study is different than previous studies on this topic. Indeed, the story ignored the key finding that different hormonal therapies were associated with different heart disease risks, thus raising the possibility that treatment choices could be refined.", "answer": 0}, {"article": "The U.S. drugmaker on Monday said patients taking the approved 2 milligram dosage of Keytruda and those taking an experimental 10 milligram dose had longer overall survival compared with those taking docetaxel, a standard treatment for non small cell lung cancer (NSCLC), the most common form of lung cancer. Keytruda thereby met its main goal of the study.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does explain, in broad terms, the novel way in which Keytruda and a competing cancer immunotherapy drug, work. The story also talks about the expected economic impact of cancer immunotherapies broadly. So we\u2019ll give the benefit of the doubt on the rating. However, it\u2019s not clear how many cancer immunotherapy drugs are on the market \u2014 just these two? A dozen? More? The story also doesn\u2019t tell readers how many of these drugs are approved for use against lung cancer. Is it just Keytruda?", "answer": 1}, {"article": "But when the patients were re-examined at 6 and 12 months, the results were substantially different. Over all, people who received cortisone shots had a much lower rate of full recovery than those who did nothing or who underwent physical therapy. They also had a 63 percent higher risk of relapse than people who adopted the time-honored wait-and-see approach. The evidence for cortisone as a treatment for other aching tendons, like sore shoulders and Achilles-tendon pain, was slight and conflicting, the review found. But in terms of tennis elbow, the shots seemed to actually be counterproductive. As Bill Vicenzino, the chairman of sports physiotherapy at the University of Queensland in Australia and senior author of the review, said in an e-mail response to questions, \u201cThere is a tendency\u201d among tennis-elbow sufferers \u201cfor the majority (70-90 percent) of those following a wait-and-see policy to get better\u201d after six months to a year. But this is not the case for those getting cortisone shots, he wrote; they \u201ctend to lag behind significantly at those time frames.\u201d In other words, in some way, the cortisone shots impede full recovery, and compared with those adopting a wait-and-see policy, those getting the shots \u201care worse off.\u201d Those people receiving multiple injections may be at particularly high risk for continuing damage. In one study that the researchers reviewed, \u201can average of four injections resulted in a 57 percent worse outcome when compared to one injection,\u201d Dr. Vicenzino said.\nWhy then does a cortisone shot, an anti-inflammatory, work in the short term in noninflammatory injuries, providing undeniable if ephemeral pain relief? The injections seem to have \u201can effect on the neural receptors\u201d involved in creating the pain in the sore tendon, Dr. Khan said. \u201cThey change the pain biology in the short term.\u201d But, he said, cortisone shots do \u201cnot heal the structural damage\u201d underlying the pain. Instead, they actually \u201cimpede the structural healing.\u201d\nSo the question of whether cortisone shots still make sense as a treatment for tendinopathies, especially tennis elbow, depends, Dr. Khan said, on how you choose \u201cto balance short-term pain relief versus the likelihood\u201d of longer-term negative outcomes. In other words, is reducing soreness now worth an increased risk of delayed healing and possible relapse within the year?\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\nThe article specified that steroid injections have been employed for roughly half a century.\n", "answer": 1}, {"article": "LONDON (Reuters) - Taking low doses of aspirin can reduce the risk of many kinds of cancer, scientists said on Tuesday, and the evidence is strong enough to suggest people over 40 should take it daily as protection.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\n\n\nThe story fails to distinguish between previous reports (that were based on either observational studies of people or experiments in animals) and this report that uses data from human experiments on heart disease prevention, so it is not clear to readers what is new about this latest report.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Clearly oophorectomy is not a new idea.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story reports that this is the first trial to show a reduction in major cardiovascular events among patients taking this type of fish oil derivative.", "answer": 1}, {"article": "After two weeks, blood sugar control, as measured by an oral glucose tolerance test, improved for those in the CPAP group compared to the oral placebo group. In addition, the ability of insulin to regulate their blood sugar, estimated by the intravenous glucose tolerance test, was improved in the CPAP group compared to the oral placebo group. The CPAP group had, on average, 27 percent lower levels of the stress hormone, norepinephrine, as well as lower blood pressure than the oral placebo group.\nFor this study, the researchers recruited 39 middle-aged, overweight or obese volunteers with prediabetes and sleep apnea. Two-thirds of them (26) were randomly assigned to two weeks of CPAP treatment. The other 13 received a placebo -- a pill containing no medicine -- to be taken 30 minutes before bedtime. They were told the study would compare the two treatments.\n\"Our study showed that CPAP in patients with prediabetes can lower their risk of progressing to diabetes when CPAP is used for eight hours, a full night's sleep,\" said the study's lead author, Sushmita Pamidi, MD, a former fellow at the University of Chicago who is now on the faculty at McGill University in Montreal, Canada.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "This is one of the main limitations of the release. An online search shows that a number of studies have been done on the impact of CPAP use on patients with prediabetes and on patients with type 2 diabetes. The news release does not make clear how this most recent paper expands on the previous work \u2014 and it is important for releases like this one to place the new study in context.", "answer": 0}, {"article": "This phenomenon is known as a \"health halo,\" an aura of healthfulness attached to a product based on labels like \"low-fat\" \"all-natural\" or \"made with whole grains\" that seduces consumers into overeating. According to a study by the FTC, this halo effect can even lead people to overlook warning statements -- about the high sodium content of a product, for example.\n\"If a cell phone company told you they tested all the models and their model came out the best, would you believe it? Probably not,\" says Dr. Lenard Lesser, M.D., one of the co-authors of that study and a researcher at UCLA. \"The same is true with nutrition research, but the stakes are higher because we're putting our bodies at risk.\"\nIffy health claims don't mean that products like pomegranate juice should be avoided at all costs, says Keri Gans, R.D., a spokesperson for the American Dietetic Association. As long as consumers limit themselves to 8-ounce servings and products with no added sugar, juice can be an excellent source of vitamins and other nutrients, Gans says. But it's \"not going to solve any of your health issues,\" she adds.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that POM is hardly the only juice drink making questionable health claims. VitaminWater, kombucha tea, coconut water, and juice drinks made from acai, goji berry, and mangosteen are all mentioned as promoting health claims on their labels.", "answer": 1}, {"article": "Colorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\nThis study was presented at a medical conference. The findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release. \u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story did not provide insight about the historical context for this work. \u00a0For example, there are studies dating back 20 years raising questions about whether this class of medication influences cancer risk.", "answer": 0}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The relative novelty of the approach and of the new study is clear in the story.", "answer": 1}, {"article": "This study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals. Unlike deep brain stimulation, dTMS does not need an operation or implantation of electrodes. Instead, an electromagnetic coil is placed on the scalp and sends magnetic pulses to stimulate specific deep regions of the brain. Currently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\nThe research team also measured blood levels of glucose (sugar), insulin, pituitary gland hormones and neurotransmitters such as norepinephrine. Pituitary hormones play a key role in regulating appetite, and recent research shows that norepinephrine and other neurotransmitters affect microbiota composition, Luzi said.\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release confirms that dTMS has been around for a while and is used to treat other conditions, but highlights that using the procedure to treat obesity is a new area of exploration.", "answer": 1}, {"article": "CHICAGO (Reuters) - Women derive twice the benefit from a device to treat heart failure as men, U.S. researchers said on Monday, underscoring the different ways in which men and women experience heart disease.\nIn the MADIT-CRT trial, women were more likely to suffer heart failure caused by a viral infection of the heart, whereas in men, the condition is more often caused by blocked heart arteries, Moss said.\n\u201cOur finding was unexpected, but extremely important because this is the only heart treatment that is clearly better in women than men,\u201d Dr. Arthur Moss of the University of Rochester Medical Center, whose study appears in the Journal of the American College of Cardiology, said in a statement.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It seemed clear from the story that the combination device was not new but that its use had recently been expanded.", "answer": 1}, {"article": "Scientists have transformed one type of fully developed adult cell directly into another inside a living animal, a startling advance that could lead to cures for a variety of illnesses and sidestep the political and ethical quagmires\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The approach described \u2013 while novel \u2013 is certainly not unique (viral vector for treatment of a chronic disease).\u00a0 Additional comments on the approach used by other reseachers would have added a needed balance.\n\u00a0", "answer": 0}, {"article": "\u2022 If you have any question or request regarding interview opportunities, please contact:\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain. \"This message should be relayed by general practitioners, who play a key and essential role in promoting exercise behaviour in the elderly,\" he said. \"Even a little is good, and more may be better.\"\nNow, a study in a French cohort of more than 1000 elderly subjects (the PROOF study) has found a negative correlation between their level of physical activity and risk of all-cause death, suggesting that in the elderly (as in other population groups) the risk of death decreases with greater and more regular exercise.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "There have been numerous studies on the benefits of exercise for the general population. Physicians currently recommend exercising for 30 minutes a day for at least five days a week, which \u201chas been shown to reduce the average risk of death by 30%,\u201d according to an uncited source in the news release.\nWhat\u2019s new, says the news release, is that \u201ca correlation between the level of physical activity and risk of death has not been so clearly determined in the elderly.\u201d\nBut we found these studies online, some going as far back as 1989, that state the association between regular physical activity and decreased mortality in older adults. In addition, recommendations are already in place for older adults, who are urged to exercise moderately and daily by the CDC.\nWe\u2019re not sure why the physical activity recommendations for the elderly warrant revision, as stated by the release, or what exactly is new with this research.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Fast food outlets should hand out free cholesterol-lowering statin drugs to their customers to \u201cneutralize\u201d the heart risks of eating fatty foods like burgers and fries, British scientists suggested on Thursday.\n\u201cIt makes sense to make risk-reducing supplements available just as easily as the unhealthy condiments (such as salt or ketchup) that are provided free of charge,\u201d Francis said in his report of the research. \u201cIt would cost less than 5 pence ($0.07) per customer \u2014 not much different to a sachet of ketchup.\u201d\nFrancis\u2019 team \u2014 who worked independently and had no funding from the drug or food industries for their research \u2014 used data from a previous large study to quantify how a person\u2019s heart attack risk increases with their daily intake of total fat and harmful trans fats.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This would definitely be novel, and the story makes that clear. What it does not do, unfortunately, is to emphasize that this wasn\u2019t\u00a0a study\u00a0based on\u00a0people eating fast food and then taking statins. There was only one line very late in the story explaining that the researchers \"used data from a previous large study\" and that they did a comparison \"using data from seven previously published trials.\"\u00a0 ", "answer": 1}, {"article": "Prostate cancer is the second leading cause of cancer death in men. According to the National Cancer Institute, about 32,050 men died from prostate cancer in 2010 and 217,000 new cases were diagnosed. More than 2.2 million men in the U.S. are living with prostate cancer.\nFor the study, the researchers looked at data from 78,485 men who participated in the longitudinal Cancer Prevention Study II Nutrition Cohort, answering questions about diet and drug use every two years starting in 1992. During the follow-up, there were 8,092 cases of prostate cancer \u2014 significantly fewer in the group who took acetaminophen daily for five years.\nRichman and colleagues noted that the brisk walks may reduce insulin resistance, which decreases bioavailable insulin-like growth factor-1 (IGF1) and increases adiponectin levels, which are all associated with decreased risk of advanced or fatal prostate cancer in vitro and in vivo. Another potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story explained that there\u2019s been prior research in both fields \u2013 studying effects of anti-inflammatory drugs and walking on prostate cancer.\nSo it didn\u2019t inappropriately paint either pursuit as totally new.", "answer": 1}, {"article": " IVM is an experimental fertility treatment that collects and matures a woman\u2019s eggs in a lab. Although the treatment is used in conjunction with IVF, the initial process isn\u2019t the same.\nIVM can also help women who are adverse to injections or who have failed IVF, Luk said.\nClinics that specialize in IVM require a doctor who has expertise in retrieving small eggs and a lab with embryologists who have the skills to look for them, said Dr. Janelle Luk, medical director of Neway Fertility in New York City.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "As mentioned earlier, it\u2019s hard to say just why Fox is presenting this as \u201cnews now.\u201d", "answer": 0}, {"article": "SAVI SCOUT replaces a more inconvenient technique used since '70s\n\u201cWhen Madrigrano told me about it, I thought it was an ingenious idea and I\u2019m glad it was developed,\u201d said Nancy Morrissey, who underwent lumpectomy surgery at Rush in July using the SAVI SCOUT technology. \u201cIt made surgery go smoothly, and I didn\u2019t have any pain before or after.\n\u201cUltimately, this wireless technology has the potential to reduce surgical delays, and more importantly will benefit patients by increasing comfort and satisfaction during a stressful time,\u201d Madrigrano said.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The news release claims that the Savi Scout is novel and that Rush is the first institution in Illinois to deploy the technology.", "answer": 1}, {"article": "Now, with support from Ohio State\u2019s Center for Clinical and Translational Science (CCTS), researchers from both the College of Engineering and the College of Medicine are taking the technology to the next level. Working with a mechanical and aerospace engineering team led by Shaurya Prakash, PhD and Vish Subramaniam, PhD, the scientists have optimized the bandage\u2019s design and the amount of electrical current delivered. Like present WEDs, the new prototype is flexible, portable and self-contained. Made of silk and silver, the experimental dressing includes a self-contained battery that delivers a continuous, safe, low-level electrical current to the injury. \u201cWe\u2019re hoping this new design may allow electric fields and currents to penetrate more deeply into wounds, and really get to where these biofilms may be hiding,\u201d said Subramaniam, chair of the Department of Mechanical and Aerospace Engineering at Ohio State. \u201cThe destruction of the biofilm would enable antibiotics to start killing off bacteria, reduce chronic inflammation and allow the body\u2019s natural immune response to work more effectively. Bacteria are known to quickly acquire resistance against antibiotics, but to our knowledge, bacteria do not develop resistance against electroceuticals.\u201d To test the experimental design, Roy and a team of scientists developed an animal model to mimic the skin function of a person suffering from metabolic syndrome \u2013 obesity, high blood pressure, high blood sugar - which mirrors the type of patient that typically develops chronic wounds. Animal models had skin injuries infected with Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii, three different types of bacteria that commonly infect wounds and develop biofilms that are treatment resistant.\n\u201cA wound naturally produces its own electrical fields that help reduce bacteria and promote cell regeneration; however, this function is likely impaired in chronic wounds,\u201d said Sashwati Roy, PhD, an Associate Professor in the Department of Surgery at Ohio State\u2019s College of Medicine. \u201cThe prototype dressing mimics this physiological process, and while it has proven to create an optimal environment where chronic wounds can heal, we are always looking for new ways to keep pathogens under better control.\u201d\nRoy notes that chronic wounds are particularly susceptible to infection because bacteria, which at times are free floating within a wound \u2013 can sometimes mobilize, creating colonies covered by a thick sticky coating called a biofilm. The immune system cannot penetrate the biofilm, and antibiotics can\u2019t get in either \u2013 causing constant inflammation and low-level infection that can further dampen the healing process.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "As the news release points out,\u00a0FDA-approved\u00a0WEDs already exist on the market. What is the real novelty here? We are told:\n\u201cThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\u201d\nBut the release never explains what these\u00a0significant advances are.", "answer": 0}, {"article": "Funding for the study was provided by the Commonwealth Fund (5P01 CA015396, P30 CA006973) and the Baca and Morisi Funds.\nOne year after receiving the MILs therapy, 13 of the 22 patients had at least a partial response to the therapy, meaning that their cancers had shrunk by at least 50 percent.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "We like the fact that the headline itself defines this as a \u201cpilot\u201d clinical trial and that the lede says that it is \u201cwhat is believed to be the first small clinical trial of its kind.\u201d\u00a0 Those kinds of qualifiers both declare the specifics of the research and also provide informative caveats, allowing the reader to gauge how much credence to give to the findings.\u00a0 All too many other medical releases fail to provide this measured approach.", "answer": 1}, {"article": "Menopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis. Hormone therapy may help relieve a woman's menopausal symptoms but is not recommended for women who have had breast cancer.\nSanten and colleagues reviewed controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies to address the gap in treatment recommendations for management of menopausal symptoms after breast cancer.\n\"Following breast cancer, women should generally not be treated with menopausal hormone therapy but should instead focus on lifestyle modifications such as smoking cessation, weight loss, and regular physical activity,\" said the study's first author, Richard J. Santen, M.D., of the University of Virginia Health System in Charlottesville, Va. \"Pharmacologic agents are also available to treat women with severe symptoms. The most important thing to remember is that therapy must be individualized based on each woman's needs and goals.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "Besides listing lifestyle approaches which are not novel, it\u2019s unclear if the emerging approaches listed are novel.", "answer": 0}, {"article": "And another mainstream expert is much more disapproving. William E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\nDr. Arnold said that if the results bore out that neurofeedback was making the difference, he would seek financing for a broader study, with as many as 100 subjects.\nWhen it comes to to the actual devices, Dr. Kerson, at the International Society for Neurofeedback and Research, cautioned that they should never be used without experienced supervision.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "\u00a0The story seemed to provide a nice history of neurofeedback devices from the 1960\u2019s.", "answer": 1}, {"article": "For more on fertility and cancer treatments, visit the American Cancer Society.\nWith this procedure, many women who survive cancer should be able to become pregnant and have healthy children, Jensen said.\nFor the study, the researchers reviewed the outcomes of 53 transplantations of thawed ovarian tissue in 41 Danish women. The investigators followed the women for 10 years, looking at ovarian function, fertility and safety.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Apparently, it isn\u2019t new to remove an ovary and freeze it. Some of the patients in the study had that done 15 years ago. The story establishes this and explains that the study is new in that it reports on longer-term outcomes.", "answer": 1}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article does a good job of noting that there are other studies past and planned designed to test the value of bariatric surgery compared to other interventions for obesity and diabetes.", "answer": 1}, {"article": "\"What I noticed in my son was not necessarily that he'd stop losing things at school or do his homework better,\" she says. \"The improvement I saw was that he was easier to live with.\"\nThe results should be out within a few weeks, Arnold says. In the meantime, he says, the study has shown that it is possible to do neurofeedback research that involves a placebo.\n\"Parents do need to know that relative to treatments like medication treatment, to behavior therapy, at this point, the research base is not as extensive,\" Rabiner says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not oversell the novelty of neurofeedback for the treatment of ADHD.", "answer": 1}, {"article": "Shares of Zafgen, which traded as high as $55.36 on the Nasdaq stock exchange last year, closed Tuesday at $5.62, down nearly 3.3 percent for the day.\nZafgen said its six-month study involving 107 patients suffering from Prader-Willi syndrome met its two primary goals, known as end points: showing significant weight loss by many patients and a decrease of hyperphagia-related behavior, meaning excessive eating.\n\u201cWe\u2019re delighted with the results,\u201d Hughes said in an interview. \u201cThis is the first demonstration of a clinical benefit against two of the major issues that affect this patient population. Our intention is to provide a plan for moving forward with an emphasis on patient safety.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Having stated that there are currently no treatments for Prader-Willi, the novelty of the beloranib should be\u00a0self-evident to the reader.", "answer": 1}, {"article": "Taking aspirin every day may lower the risk for prostate enlargement, a new study has found. Other nonsteroidal anti-inflammatory drugs, or Nsaids, like naproxen (Aleve) or ibuprofen (Advil or Motrin), have the same effect.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist. \u201cSo this is a possible fringe benefit.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story names the drugs studied\u2013aspirin, naproxen, and ibuprofen\u2013none of which is new to the market. This is a new use of existing medications. ", "answer": 1}, {"article": "COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nLead researcher Martin Reck of Germany\u2019s Lung Clinic Grosshansdorf predicted that testing for the PD-L1 biomarker would now become standard \u201cfrom today\u201d.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story establishes that these findings reveal that immunotherapy works better when patients are prescreened for a specific genetic marker known as PD-L1, versus giving it to anyone with this type of cancer. It also\u00a0explains that the smaller second trial, mixing Keytruda with chemotherapy, was \u201cthe first time that a combination of immunotherapy and chemotherapy has been shown to work in a randomized Phase II study.\u201d", "answer": 1}, {"article": "Soy supplements also have side effects such as nausea, bloating, and constipation, according to the National Institutes of Health. A month\u2019s supply costs about $12, while a month of hormone tablets runs between $40 and $60.\nThe new study, published in the journal Menopause, is based on 90 Chinese women. A third of them received placebo pills made of starch, while the rest took soy germ isoflavones, either 84 or 126 milligrams a day.\nThe new study didn\u2019t find significant hormone changes in women who took soy supplements, and Wong said the compounds are probably safe for women.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story at least establishes that there has been other past research on soy supplements and hot flashes, quoting an American researcher.", "answer": 1}, {"article": "Doctors run many different tests to assess someone\u2019s risk of heart disease. They measure cholesterol, blood pressure and heart rate, they test the electrical signals that keep the heart beating and they may also run imaging tests to check for clogged arteries.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\n\u201cWe are now further validating our method in larger numbers of patients in large prospective clinical studies to document and confirm the predictive value of this method for future heart attacks,\u201d Antoniades said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story focuses on the use of inflammatory heart tissue as having potentially better predictive value than current risk assessment tools for heart attack. But it\u2019s a reluctant satisfactory, because the narrative is confusing and no\u00a0numbers were given to estimate the scope of the potential benefit\u2013how well the new approach worked.", "answer": 1}, {"article": "A group of 1,537 women were randomly assigned to a daily diet that included five vegetable servings, three fruit servings, 16 ounces of vegetable juice and 30 grams of fiber. They also tried to consume no more than 20 percent of their calories from fat. An additional 1,551 women were given only materials about the importance of eating five servings of fruits and vegetables a day.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story mentions that this is a newly published study showing no evidence that a diet high in fruits and vegetables is not directly related to a decreased risk of breast cancer recurrence.\u00a0 Increasing fruits/vegetables in the diet is not a novel concept. ", "answer": 1}, {"article": "The results appear in Nutrition Journal.\n\u201cIt\u2019s promising that we can see an effect from a single dose,\u201d says researcher Leah Coles, PhD, a research fellow at the Baker IDI Heart and Diabetes Institute in Melbourne, Australia. \u201cThat effect might be even greater over the long term if they are drinking it day upon day.\u201d\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that previous research has shown a blood pressure-lowering effect for beet juice in a laboratory setting.", "answer": 1}, {"article": "\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health. Behavioral counseling is widely recommended, with medication, to help smokers quit.\nThe results of the new study are published online in Tobacco Control. The findings are at odds with clinical trials, Connolly says. The new study, however, draws from the population. It gives a more ''real world'' picture, he tells WebMD.\nRelapse rates of the quitters were similar during the study period, whether they used the products alone or with counseling, or they did not use them.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story says that the new study gives a more \u201creal world\u201d picture of nicotine replacement therapies.", "answer": 1}, {"article": "WASHINGTON (Reuters) - Commonly used diabetes drugs such as metformin may help control lung cancer, and may help prevent it, U.S. researchers reported on Tuesday.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Dr. Mazzone tells us what\u2019s unique and not unique about the study. As we pointed out under the \u201cevidence\u201d criterion, his quote may be the source of some confusion, but he is clear about what\u2019s unique.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story was correct in presenting the \"paint\" as a new possible adjunct to the methods used for determining tumor boundaries.", "answer": 1}, {"article": "It all started 10 years ago after an operation for a knee injury.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\n\"That's the hope,\" says Lapook. \"Whatever the cause, it dials down the pain on the brain center. With chronic pain you have to throw the kitchen sink at it. That means integrative medicine, acupuncture, massage, medication in as low doses as possible.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The segment makes clear that while this particular application of electrical stimulation is novel, it has been in development and used for other purposes for many years. ", "answer": 1}, {"article": "As exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\" Gulley is director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology, National Cancer Institute.\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD. \"In January, it will be four years [for her],\" he tells WebMD.\nResults of the vaccine were not as good in the other 25 patients. For them, the median time before the cancer progressed was about two months.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The concept of vaccines for breast/ovarian cancer is indeed novel, and the story acknowledges that other vaccines are being studied.", "answer": 1}, {"article": "Lung cancer is the most common cause of cancer death in the U.S. for men and women. Non-small cell lung cancer constitutes about 85-90% of lung cancer cases.\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\nThe Dana-Farber scientists say current [EGFR] inhibitors Iressa and Tarceva prevent EGFR from sending signals that are essential to keep tumor cells growing, the researchers say.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The article describes the novelty of the compound.", "answer": 1}, {"article": "However, this has been shown to be false. Worse, these same people tend to promote abstinence-only education, which has been shown conclusively to be the worst possible sex education; kids taught his way tend to have more pregnancies and more STIs than ones who are taught progressive, healthy sex ed.\nThe study, published in the Pediatric Infectious Disease Journal, looked at the published data about effects from the vaccine and found that it has a \u201cfavorable safety profile.\u201d This study comes after many other previous studies that show essentially the same thing. There is no correlation between getting the Gardasil vaccine and seriously adverse effects such as \u201cautoimmune diseases (including Guillain-Barre Syndrome and multiple sclerosis), anaphylaxis, venous thromboembolism, and stroke.\u201d\nThe Gardasil vaccine, on the other hand, caused some people to faint after getting it, and others got mild skin infections\u2014both of which occur somewhat rarely with other vaccines too, as you might expect.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story notes that the study driving the coverage is \u201cnew,\u201d but beyond that doesn\u2019t establish what is different or interesting about this research compared with previous studies.", "answer": 0}, {"article": "Advanced tumors were found in about 30 percent of the patients who had never been screened but in just over 5 percent of those who had mammograms.\nThe study, however, has some limitations, Bernik noted. It's not clear, for instance, whether the women who died of cancer got less aggressive treatment or refused treatment. That could have affected survival, of course.\nThe study findings ''add to the body of evidence supporting the fact that mammography matters in improving detection and survival,\" said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City. \"This study focuses on survival.\"\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Screening mammography is not a new approach to detecting breast cancer.", "answer": 2}, {"article": "For more information on breast cancer, visit the American Cancer Society.\n\"The results of this laboratory study are intriguing,\" McCullough said. \"But before recommending bitter melon extract supplements for cancer prevention, we need appropriate clinical trials to establish its safety and efficacy in humans.\"\nMarji McCullough, strategic director of nutritional epidemiology at the American Cancer Society, expressed interest in the findings.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There\u2019s been a lot of research for a long time on bitter melon extract.\u00a0 We quickly found one study from as far back as 1983.\u00a0 The story didn\u2019t provide any of that context. ", "answer": 0}, {"article": "\u2022 23% had to start or increase blood pressure medication, compared to 7% getting a placebo. There's at least one theoretical concern about R788. Normally, the Syk enzyme helps suppress tumors. Women with breast tumors have low levels of Syk. It's not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk. For now, R788 looks very promising, the researchers report. \"Inhibition of the Syk pathway offers a new drug target for rheumatoid arthritis,\" Weinblatt and colleagues conclude. The Weinblatt study and an editorial by NIH researchers Juan Rivera, PhD, and Robert A. Colbert, MD, PhD, appear in the Sept. 30 issue of the New England Journal of Medicine. Rigel funded the study, and three of the study's six authors are Rigel employees. Weinblatt reports receiving grants, fees, or honoraria from a number of drug and biomedical companies, including Rigel.\nSept. 28, 2010 -- An experimental rheumatoid arthritis treatment helps two-thirds of patients getting too little relief from methotrexate. The drug, from a company called Rigel, is R788 or fostamatinib disodium. The oral drug targets an enzyme called Syk. Nobody is exactly sure of the role Syk plays in rheumatoid arthritis. But there's an overabundance of Syk in the fluid of arthritic joints, and the enzyme is part of the runaway immune machinery that increases joint inflammation.\nThe drug does have side effects. Among patients getting the twice-daily 100 milligram dose:\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The lead of the story says, \"An experimental rheumatoid arthritis treatment helps two-thirds of patients getting too little relief from methotrexate.\"\u00a0But the story itself fails to explain how these two drugs interact, if at all. If this drug is truly novel, is it a replacement for the other drug or an enhancement?\u00a0Have other drugs been tested in this same vein?\u00a0Are there competitors in trials, too?", "answer": 0}, {"article": "Rather, he says it\u2019s because facial expressions are part of the circuit of the brain related to mood.\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression. Finzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cIt wasn\u2019t effective. Some side effects would be headaches or stomachache,\u201d she told CBS News.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "Botox has already been promoted for \u201coff label\u201d use to treat depression for some time. HealthNewsReview.org has previously explored the marketing of botox for depression and other conditions. Not only is evidence not presented well, but the news isn\u2019t novel, either.", "answer": 0}, {"article": "In laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs. The laparoscope is a slender tube that allows the surgeon to see inside the body. Most minimally invasive prostate operations are robot assisted.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story plainly states that the procedure is increasingly common and widely advertised. It cites figures from the study that demonstrate the increase of use between 2003 and 2005. ", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story establish the true novelty of the approach?", "explanation": "Novelty in this story is not so much about the treatment itself, which the article states has been a research focus since about the year 2000. The novelty here resides in the scope and expense of these clinical trials. The\u00a0story\u00a0makes that clear.", "answer": 1}, {"article": "Clostridium novyi has been linked to human illness. In 2000, the U.S. Centers for Disease Control and Prevention reported that a handful of drug users in the United Kingdom fell ill or died after their injection sites became infected with the bacteria.\nThe scientists expected Clostridium novyi-NT to help fight the tumor in two ways.\nFollowing bacterial therapy, cancer stabilized in 21 patients. When both injected and uninjected lesions were included, the stable disease rate was 86 percent, the researchers reported.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story does not establish the novelty of the research. The abstract describes this as a \u201cfirst-in-man\u201d trial of weakened clostridium novyi spores in cancer patients.\nIn general, though, bacterial therapies for cancer tumors have been studied for decades, although only recently have safer forms been available.", "answer": 0}, {"article": "\u2022 Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;\n\"The current form of radiation is 44 treatments given over nine weeks. In contrast, the SBRT therapy we used allows the delivery of highly focused radiation in only five treatments, allowing patients to return to their normal lives more quickly,\" said senior author Dr. Robert Timmerman, Director of the Annette Simmons Stereotactic Treatment Center at UT Southwestern, and Professor and Vice Chairman of the Department of Radiation Oncology. \"SBRT is both more convenient and has increased potency.\"\nTo reduce the side effects associated with SBRT, current clinical trials at UTSW are using a unique and biodegradable rectal spacer gel to protect the rectum. UTSW is currently the only accredited site in Texas at which this spacer gel can be used.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release claims that the study was the first published trial to follow patients receiving SBRT for five years.", "answer": 1}, {"article": "Learn more about mammography screening guidelines from the American Cancer Society.\n\"There are multiple benefits of mammography in terms of early detection. Not only do we save lives, but we reduce the likelihood of needing more aggressive treatment,\" said study author Dr. Elisa Port. She directs the Dubin Breast Center at Mount Sinai and is chief of breast surgery at Mount Sinai Hospital, both in New York City.\nPort noted that screening guidelines tend to be based on the ability of mammograms to save lives and how often they give a false positive result.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes clear the distinctive aspects of this study \u2014using avoidance of more aggressive treatment regimens as a deciding factor, as opposed to the more extreme avoidance of cancer death.\n", "answer": 1}, {"article": "Strokes are the third leading cause of death in the United States and a major cause of disability among adults. Each year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\nDr. Walter J. Koroshetz, deputy director of the institute that sponsored the North American trial, said the Crest trial was the first in which the results of stenting and surgery had been found to be equivalent \u2014 suggesting that the stent procedure had improved with time.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "It\u2019s clear from the story that both of these approaches have been in use for quite some time. ", "answer": 1}, {"article": "Stents have been increasingly used in people with clogged arteries who are not having heart attacks, but some studies suggest that those patients would be better off taking drugs to reduce cholesterol, inflammation and clotting. The reasoning is that artery disease tends to be systemic and extensive, but stents can treat it only in tiny spots.\nIn an editorial accompanying the study in the journal, two other cardiologists say that late angioplasty may still be worthwhile for some patients. The ones who might benefit, they say, are a small minority \u2014 perhaps 10 to 15 percent \u2014 who cannot take the class of heart medicines known as beta blockers, which have been proved to increase survival after a heart attack.\nDr. Hochman emphasized that angioplasty was still the best treatment for many heart attack patients who go to the hospital early, within 12 hours of when the attack began. The people who generally do best are those who arrive at the hospital and have angioplasty within 90 minutes of the heart attack.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The treatment discussed in the story is not a novel treatment nor was it portrayed as such.", "answer": 1}, {"article": "Mr. Del Sontro is all too aware that the cause of his heart disease is a mystery, but he worries that if he fails to eat right and exercise he might make his illness even worse.\nDr. Biesecker acknowledged that there was no guarantee of success. He and his colleagues know the gene mutation in the Del Sontro family must be rare. Otherwise, lots of people would have early heart disease but no obvious risk factors. To keep the focus on truly rare mutations, the researchers are excluding those that are present in both members of the Del Sontro family and 3 percent or more of the other study participants. That strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nThe researchers are now searching for culprits among genes that remain \u2014 a search that could take years. Or the change might be in a poorly understood region of DNA that controls genes rather than in a gene itself. Researchers\u2019 ignorance of these control regions and what many of them do might doom the effort. So the researchers are hoping the Del Sontro family\u2019s heart disease is caused by a mutated gene.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "This research is certifiably novel, although other studies have looked for genetic determinants.", "answer": 1}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes plain that the surgery is commonly done and makes no claim for its novelty. ", "answer": 1}, {"article": "Spit Test May Reveal The Severity Of A Child's Concussion\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year. Many of the injuries are related to sports.\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "A spit test to predict the duration of concussion symptoms would indeed be new. Also, the description of the background of the independent source in the story notes that he is also working on using microRNA tests to better understand traumatic brain injury, so readers and listeners are told that other researchers are studying similar approaches.", "answer": 1}, {"article": "Fasting has been deployed since the ancient Greeks to fast-track learning. As Plato is said to have stated, \u201cI fast for greater physical and mental efficiency.\u201d The philosopher Pythagoras reportedly demanded that his students fast 40 days before attending his lectures.\nLast spring, 100 people showed up at a Peak Performance event where psychedelic psychologist James Fadiman said the key to unleashing the cognition-enhancing effects of LSD \u2014 which he listed as less anxiety, better focus, improved sleep, greater creativity \u2014 was all in the dosage. He recommended a tenth of a \u201cparty dose\u201d \u2014 enough to give you \u201cthe glow\u201d and enhance your cognitive powers without \u201cthe trip.\u201d\nBut while some studies have found short-term benefits, Doraiswamy says there is no evidence that what are commonly known as smart drugs \u2014 of any type \u2014 improve thinking or productivity over the long run. \u201cThere\u2019s a sizable demand, but the hype around efficacy far exceeds available evidence,\u201d notes Doraiswamy, adding that, for healthy young people such as Silicon Valley go-getters, \u201cit\u2019s a zero-sum game. That\u2019s because when you up one circuit in the brain, you\u2019re probably impairing another system.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "There story gives perspective, mentioning that piracetam has been around for decades, though newer formulations are on the market, and that companies have recently begun marketing \u201cstacks\u201d with multiple supplements.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story focuses on an active debate, rather than on a new technique, technology, or drug. There are no claims to novelty, so we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "About three-fourths of the U.S. population aged 75 and older live with hypertension, a leading contributor to cardiovascular disease and death. Although the standard blood pressure treatment goal is 140 mm Hg, various medical panels have provided inconsistent guidance about what is the optimal blood pressure goal for the senior population. One group has recommended a target blood pressure of 160 mm Hg for persons aged 80 or older, while another recommended a target of 150 mm Hg for adults aged 60 or older. Other experts have supported keeping the standard treatment goal at 140 mm Hg.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent. This lower blood pressure goal also reduced the risk of death among this group by 32 percent, compared to a target systolic pressure of 140 mm Hg. The benefits of a more aggressive blood pressure intervention occurred in both frail (individuals with several impairments or disorders) and non-frail older participants, the researchers note.\nWHO: Lawrence Fine, M.D., chief of the Clinical Applications and Prevention Branch at NHLBI and a co-author of the study, is available to comment on the findings and implications of this research.\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release doesn\u2019t claim novelty. Instead, it makes it clear that the latest results reinforce earlier findings about blood pressure management and stresses that the latest results are \u201creporting additional details about a widely-publicized study.\u201d", "answer": 1}, {"article": "Better known as an anesthetic or as an illicit hallucinogenic drug, ketamine has also long been noted for alleviating depression. But ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients. Now, in the largest study of its kind, researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego mined the FDA Adverse Effect Reporting System (FAERS) database for depression symptoms in patients taking ketamine for pain. They found that depression was reported half as often among the more than 41,000 patients who took ketamine, as compared to patients who took any other drug or drug combination for pain.\n\"While most researchers and regulators monitor the FAERS database for increased incidences of symptoms in order to spot potentially harmful drug side effects, we were looking for the opposite -- lack of a symptom,\" Cohen said.\n\"Current FDA-approved treatments for depression fail for millions of people because they don't work or don't work fast enough,\" said senior author Ruben Abagyan, PhD, professor of pharmacy. \"This study extends small-scale clinical evidence that ketamine can be used to alleviate depression, and provides needed solid statistical support for wider clinical applications and possibly larger scale clinical trials.\"\n", "question": "Does the news release establish the true novelty of the approach?", "explanation": "The release refers often to this study being the largest of its kind and the first \u201clarge-scale\u201d study of ketamine for depression. The second sentence might lead some people to believe that this analysis is a large clinical trial \u2014 which it is not.\nThe research is novel only in its approach to claiming a benefit where there is no clear-cut relationship.\nKetamine has been tested in several small studies and research is on-going.\nThe release establishes some novelty with this statement: \u201cWhile most researchers and regulators monitor the FAERS database for increased incidences of symptoms in order to spot potentially harmful drug side effects, we were looking for the opposite \u2014 lack of a symptom.\u201d But the fact remains, this is questionable science.", "answer": 0}, {"article": "Learn more about screening mammograms by visiting the U.S. National Cancer Institute.\n\"This study will only add to the confusion for women and their physicians,\" said Dr. Daniel B. Kopans, director of breast imaging at Massachusetts General Hospital and a radiology professor at Harvard Medical School.\n\"That physicians are still debating the relative merits of screening mammography despite the wealth of data suggests that the test is surely a close call, a delicate balance between modest benefit and modest harm,\" Welch wrote.\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story makes it clear that, far from novel, mammography is a frequently used screening procedure that is coming under new scrutiny because of mounting evidence that it does not produce the benefits early research showed.", "answer": 1}, {"article": "Provent does too, but in a different way. The device contains two pinhole-size valves, one over each nostril. The valves let air in easily \u2014 most people breathe through their nostrils while asleep \u2014 but there is resistance as the user exhales. That resistance creates a backpressure in the airways, dilating the muscles that would otherwise collapse in the middle of the night. In the morning, the patch is removed; a new one is used every night.\nDr. Surkin said some patients use C.P.A.P. at home, but take their pocket-size Provent patches with them when they travel to avoid the hassle of lugging a machine through airports.\n\u201cIt works like a champ in some people and doesn\u2019t work on other people,\u201d said Dr. Nancy Appelblatt, an ear, nose and throat surgeon in Sacramento who has prescribed it to about 100 patients. \u201cAll sleep apnea is not created equal.\u201d\n", "question": "Does the story establish the true novelty of the approach?", "explanation": "The story begins by contrasting this new treatment with the existing treatment. It says \u201cFor decades, the standard treatment has been \u201ccontinuous positive airway pressure.\u201d A mask worn at night pushes air into the nasal passages, enabling easier breathing. C.P.A.P. reduces and in some cases completely prevents episodes of apnea. But the mask is like something from a bad science fiction movie: big, bulky and obtrusive. Many patients simply refuse to wear it or rip it off while asleep. Studies show that about half of all people prescribed C.P.A.P. machines stop using them in one to three weeks.\u201d The story makes the claim that the Provent patch is \u201cfar less intrusive than the traditional C.P.A.P. machine.\u201d The claim of novelty is not backed up by the evidence presented in the story or by any published clinical trial.\u00a0 As we noted above about one out of every six people using the Provent in the study stopped using it after 3 months.", "answer": 0}]